

NEWS EXPRESS

NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),

AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

STN Operating Hours Plus Help Desk Availability NEWS HOURS

Welcome Banner and News Items NEWS LOGIN

For general information regarding STN implementation of IPC 8 NEWS IPC8

NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 19:10:40 ON 14 MAR 2007

=> file reg COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 19:10:46 ON 14 MAR 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

13 MAR 2007 HIGHEST RN 926304-31-6 STRUCTURE FILE UPDATES: DICTIONARY FILE UPDATES: 13 MAR 2007 HIGHEST RN 926304-31-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\43431.str

L1 STRUCTURE UPLOADED

=> d 11L1 HAS NO ANSWERS

Updated Search

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 11 SAMPLE SEARCH INITIATED 19:16:11 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 59 TO ITERATE

100.0% PROCESSED 59 ITERATIONS 15 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 720 TO 1640 PROJECTED ANSWERS: 68 TO 532

L2 15 SEA SSS SAM L1

=> s 11 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 19:16:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1227 TO ITERATE

100.0% PROCESSED 1227 ITERATIONS 347 ANSWERS

SEARCH TIME: 00.00.01

L3 347 SEA SSS FUL L1

=> file hcaplus COST IN U.S. DOLLARS

COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION
175.70
175.91

FILE 'HCAPLUS' ENTERED AT 19:16:20 ON 14 MAR 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Mar 2007 VOL 146 ISS 12 FILE LAST UPDATED: 13 Mar 2007 (20070313/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate

Updated Search

substance identification.

=> s 13

7 L3 L4

=> s l4 and neville, a?/au

355 NEVILLE, A?/AU

O L4 AND NEVILLE, A?/AU L5

=> s 14 and gomez, r?/au

1976 GOMEZ, R?/AU

1 L4 AND GOMEZ, R?/AU L6

=> d 16, ibib abs hitstr, 1

ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2005:158641 HCAPLUS

DOCUMENT NUMBER:

142:261546

TITLE:

Preparation of sulfonyl substituted

N-(biarylmethyl)aminocyclopropanecarboxamides as

bradykinin B1 antagonists or inverse agonists

Anthony, Neville J.; Gomez, Robert; Jolly,

Samson M.; Lim, John Jin; Su, Dai-shi

PATENT ASSIGNEE(S):

Merck & Co., Inc., USA PCT Int. Appl., 57 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

INVENTOR(S):

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PATENT NO.					KIND		DATE		APPLICATION NO.						DATE		
	WO	2005	 01688	36		A1	-	2005	0224			2004-				2	0040	803
		W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	AZ,	BA,	BB	, BG,	BR,	BW,	BY,	ΒZ,	CA,	CH,
			CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ	, EC,	EE,	EG,	ES,	FI,	GB,	GD,
												, JP,						
			LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG	, MK,	MN,	MW,	MX,	MZ,	NA,	NI,
			NO,	ΝZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU	, SC,	SD,	SE,	SG,	SK,	SL,	SY,
	-											, UZ,						
		RW:										, SL,						
												, BE,						
												, LU,						
			SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM	, GA,	GN,	GQ,	GW,	ML,	MR,	NE,
				TD,				•					_			_		
								AU 2004-265300										
	CA 2534188							CA 2004-2534188										
	ΕP	1654										2004-						
		R:										, IT,					MC,	PT,
												, CZ,						
	CN	1832	922			Α						2004-					0040	
								JP 2006-522671 US 2006-565040										
								2006	1102								0060	
PRIORITY APPLN. INFO.:											2003-							
												2003-					0030	
											WO	2004-	US25	037		W 2	0040	803
OTHER SOURCE(S):						MAR:	PAT	142:	2615	46								

GΙ

$$R^{4?}$$
 $R^{4?}$
 $R^{4?}$
 $R^{4?}$
 $R^{4?}$
 $R^{3?}$
 $R^{4?}$
 $R^{6?}$
 $R^{6?}$

N-(Sulfonyloxybiarylmethyl)aminocyclopropanecarboxamide derivs. (I) [R1, AB R2 = H, C1-4 alkyl; R3a, R3b = H, (un)substituted C1-4 alkyl; R4a, R4b =H, halogen, (un) substituted C1-4 alkyl; or R4a and R4b together with the carbon atom to which they are both attached form an (un) substituted exocyclic methylene; R5 = each (un)substituted C1-6 alkyl, C3-8 cycloalkyl, C3-6 alkynyl, C2-6 alkenyl, (CH2)k-aryl, (CH2)k-heterocycle; R6a = -OSO2R8, -NR8aSO2R9, -C(R8b)(R8c)SO2R9; R6b, R6c, R6d = H, halogen, OSO2R8, (un) substituted C1-4 alkyl, cyano, nitro, ORa, CO2Ra, or when attached to adjacent carbon atoms R6C and R6d together with the carbon atoms to which they are attached form a 5- to 8-membered saturated or unsatd. ring; R7 = H, halogen, cyano, nitro, ORa, CO2Ra, C(O)NRbRc, (un) substituted C1-4 alkyl; R8 = H, each (un) substituted C1-4 alkyl, (CH2) k-aryl, or NH2; R8a, R8b, R8c = H, (un) substituted C1-4 alkyl; or when R6a and R6b are attached to adjacent atoms, R8a and R6b together complete 5- or 6-membered ring; R9 = each (un) substituted C1-4 alkyl, aryl, or (CH2)k-aryl; Ra, Rb, Rc = H, each C1-4 alkyl or Ph, C3-6 cycloalkyl; or NRbRc together forms a cyclic imide or a 4-, 5-, or 6-membered ring optionally containing an addnl. heteroatom selected from N, O, and S; X = CH, N; Y = C, S(0); k = 0, 1, 2]. These compds. are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin Bl pathway. Thus, N-[1-[[[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]amino]carbonyl]cyclopropyl]pyrimidine-5-carboxamide was coupled with 1-bromo-3-fluoro-2-methoxybenzene in the presence of tetrakis(triphenylphosphine)palladium(0) and potassium phosphate at 110° for 16 h to give N-[1-[[[(3,3'-difluoro-2'-methoxy-1,1'biphenyl-4-yl)methyl]amino]carbonyl]cyclopropyl]pyrimidine-5-carboxamide which was treated with boron tribromide in CH2Cl2 at room temperature for 48 h to give N-[1-[[(3,3'-difluoro-2'-hydroxy-1,1'-biphenyl-4y1)methyl]amino]carbonyl]cyclopropyl]pyrimidine-5-carboxamide (II). II was stirred with tifluoromethanesulfonic anhydride in the presence of Et3N in CH2Cl2 at room temperature for 2 h to give

3,3'-difluoro-4'-[[[[1-[(pyrimidin-

5-ylcarbonyl)amino]cyclopropyl]carbonyl]amino]methyl]-1,1'-biphenyl-2-yltrifluoromethanesulfonate (III).

IT 845830-03-7P, N-[(1R)-1-(3,3'-Difluoro-2'-hydroxy-1,1'-biphenyl-4-yl)ethyl]-1-[(trifluoroacetyl)amino]cyclopropanecarboxamide 845830-07-1P, N-[(1R)-1-(5'-Chloro-3,3'-difluoro-2'-hydroxy-1,1'-biphenyl-4-yl)ethyl]-1-[(trifluoroacetyl)amino]cyclopropanecarboxamide

```
845830-25-3P, N-[(1R)-1-[2-Fluoro-4-(2-methoxy-1-
     naphthyl)phenyl]ethyl]-1-[(trifluoroacetyl)amino]cyclopropanecarboxamide
     845830-26-4P, N-[(1R)-1-[2-Fluoro-4-(2-hydroxy-1-
     naphthyl)phenyl]ethyl]-1-[(trifluoroacetyl)amino]cyclopropanecarboxamide
     845830-45-7P, N-[(1R)-1-(2'-Amino-3,3'-difluoro-1,1'-biphenyl-4-
     yl)ethyl]-1-[(trifluoroacetyl)amino]cyclopropanecarboxamide
     845830-51-5P, N-[(1R)-1-[2-Fluoro-4-(quinolin-8-yl)phenyl]ethyl]-1-
     [(trifluoroacetyl)amino]cyclopropanecarboxamide 845830-52-6P,
     N-[(1R)-1-[2-Fluoro-4-(1,2,3,4-tetrahydroquinolin-8-yl)phenyl]ethyl]-1-
     [(trifluoroacetyl)amino]cyclopropanecarboxamide
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (intermediate; preparation of sulfonyl substituted N-
        (biarylmethyl)aminocyclopropanecarboxamides as bradykinin B1
        antagonists or inverse agonists for treatment or prevention of pain and
        inflammation)
     845830-03-7 HCAPLUS
RN
     Cyclopropanecarboxamide, N-[(1R)-1-(3,3'-difluoro-2'-hydroxy[1,1'-
CN
     biphenyl]-4-yl)ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)
```

Absolute stereochemistry.

RN 845830-07-1 HCAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-(5'-chloro-3,3'-difluoro-2'-hydroxy[1,1'-biphenyl]-4-yl)ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CAINDEX NAME)

RN 845830-25-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[2-fluoro-4-(2-methoxy-1-naphthalenyl)phenyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 845830-26-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[2-fluoro-4-(2-hydroxy-1-naphthalenyl)phenyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 845830-45-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-(2'-amino-3,3'-difluoro[1,1'-biphenyl]-4-yl)ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

RN 845830-51-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[2-fluoro-4-(8-quinolinyl)phenyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 845830-52-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[2-fluoro-4-(1,2,3,4-tetrahydro-8-quinolinyl)phenyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

```
845830-02-6P, 3,3'-Difluoro-4'-[(1R)-1-[[[1-
IT
     [(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-1,1'-biphenyl-2-
    vl trifluoromethanesulfonate 845830-04-8P, 3,3'-Difluoro-4'-
     [(1R)-1-[[[1-[[(trifluoromethyl)sulfonyl]amino]cyclopropyl]carbonyl]amino]
    ethyl]-1,1'-biphenyl-2-yl trifluoromethanesulfonate 845830-05-9P
      3,3'-Difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbon
    yl]amino]ethyl]-1,1'-biphenyl-2-yl methanesulfonate 845830-06-0P
     , 5-Chloro-3,3'-difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cycloprop
    yl]carbonyl]amino]ethyl]-1,1'-biphenyl-2-yl trifluoromethanesulfonate
     845830-09-3P, 3,3'-Difluoro-4'-[(1R)-1-[[[1-
     [(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-1,1'-biphenyl-2-
     yl ethanesulfonate 845830-11-7P, 3,3'-Difluoro-4'-[(1R)-1-[[[1-
     [(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-1,1'-biphenyl-2-
     yl propane-1-sulfonate 845830-12-8P, 3,3'-Difluoro-4'-[(1R)-1-
     [[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-1,1'-
     biphenyl-2-yl propane-2-sulfonate 845830-13-9P,
     3,3'-Difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl
     []amino]ethyl]-1,1'-biphenyl-2-yl benzenesulfonate 845830-14-0P,
     3,3'-Difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl
     ]amino]ethyl]-1,1'-biphenyl-2-yl phenylmethanesulfonate
     845830-15-1P, 3,3'-Difluoro-4'-[(1R)-1-[[[1-
     [(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-1,1'-biphenyl-2-
     yl dimethylsulfamate 845830-16-2P, 3,3'-Difluoro-4'-[(1R)-1-[[[1-
     [(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-1,1'-biphenyl-2-
     yl 2,2,2-trifluoroethanesulfonate 845830-17-3P,
     3,3'-Difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl
     ]amino]ethyl]biphenyl-2-yl 4-acetylbenzenesulfonate 845830-18-4P
     , 3-Chloro-3'-fluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]c
     arbonyl]amino]ethyl]-1,1'-biphenyl-2-yl trifluoromethanesulfonate
     845830-23-1P, 3'-Fluoro-4'-[(1R)-1-[[[1-
     [(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-2-
     [[(trifluoromethyl)sulfonyl]oxy]-1,1'-biphenyl-3-yl
     trifluoromethanesulfonate 845830-24-2P, 1-[3-Fluoro-4-[(1R)-1-
     [[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]phenyl]napht
     halen-2-yl trifluoromethanesulfonate.845830-33-3P,
     N-[(1R)-1-[2'-[[4-(Acetylamino)phenyl]sulfonyl]amino]-3,3'-
     difluorobiphenyl-4-yl]ethyl]-1-[(trifluoroacetyl)amino]cyclopropanecarboxa
     mide 845830-39-9P, N-[(1R)-1-[3,3'-Difluoro-2'-
     [[(trifluoromethyl)sulfonyl]methyl]-1,1'-biphenyl-4-yl]ethyl}-1-
     [(trifluoroacetyl)amino]cyclopropanecarboxamide 845830-44-6P,
     N-[(1R)-1-[3,3'-Difluoro-2'-[[(trifluoromethyl)sulfonyl]amino]-1,1'-
     biphenyl-4-yl]ethyl]-1-[(trifluoroacetyl)amino]cyclopropanecarboxamide
     845830-50-4P, N-[(1R)-1-[2-Fluoro-4-[1-[(trifluoromethyl)sulfonyl]-
     1,2,3,4-tetrahydroquinolin-8-yl]phenyl]ethyl]-1-
     [(trifluoroacetyl)amino]cyclopropanecarboxamide
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (preparation\ of\ sulfonyl\ substituted\ N-(biarylmethyl) a minocyclopropanecarbox
        amides as bradykinin B1 antagonists or inverse agonists for treatment
        or prevention of pain and inflammation)
RN
     845830-02-6 HCAPLUS
     Methanesulfonic acid, trifluoro-, 3,3'-difluoro-4'-[(1R)-1-[[[1-
CN
     [(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2-
     yl ester (9CI) (CA INDEX NAME)
```

RN 845830-04-8 HCAPLUS

CN Methanesulfonic acid, trifluoro-, 3,3'-difluoro-4'-[(1R)-1-[[[1-[(trifluoromethyl)sulfonyl]amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 845830-05-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3,3'-difluoro-2'-[(methylsulfonyl)oxy][1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 845830-06-0 HCAPLUS

CN Methanesulfonic acid, trifluoro-, 5-chloro-3,3'-difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2-

yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$

$$O$$

$$NH$$

$$O$$

$$Me$$

$$O$$

$$O$$

$$O$$

RN 845830-09-3 HCAPLUS

CN Ethanesulfonic acid, 3,3'-difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C \longrightarrow NH \longrightarrow Me \longrightarrow O \longrightarrow O$$

RN 845830-11-7 HCAPLUS

CN 1-Propanesulfonic acid, 3,3'-difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)

RN 845830-12-8 HCAPLUS

CN 2-Propanesulfonic acid, 3,3'-difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C \longrightarrow NH \longrightarrow Me \longrightarrow O \longrightarrow O$$

RN 845830-13-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3,3'-difluoro-2'-[(phenylsulfonyl)oxy][1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 845830-14-0 HCAPLUS

CN Benzenemethanesulfonic acid, 3,3'-difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2-

yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C \xrightarrow{NH} O \xrightarrow{Me} O O O$$

RN 845830-15-1 HCAPLUS

CN Sulfamic acid, dimethyl-, 3,3'-difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 845830-16-2 HCAPLUS

CN Ethanesulfonic acid, 2,2,2-trifluoro-, 3,3'-difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)

$$F_{3}C \longrightarrow NH \longrightarrow Me$$

$$O \longrightarrow NH \longrightarrow NH$$

$$O \longrightarrow NH \longrightarrow NH$$

$$O \longrightarrow NH$$

RN 845830-17-3 HCAPLUS

CN Benzenesulfonic acid, 4-acetyl-, 3,3'-difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 845830-18-4 HCAPLUS

CN Methanesulfonic acid, trifluoro-, 3-chloro-3'-fluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 845830-23-1 HCAPLUS

CN Methanesulfonic acid, trifluoro-, 3'-fluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2,3-diyl ester (9CI) (CA INDEX NAME)

RN 845830-24-2 HCAPLUS

CN Methanesulfonic acid, trifluoro-, 1-[3-fluoro-4-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]phenyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 845830-33-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[2'-[[[4-(acetylamino)phenyl]sulfonyl]a mino]-3,3'-difluoro[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

RN 845830-39-9 HCAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-[3,3'-difluoro-2'[[(trifluoromethyl)sulfonyl]methyl][1,1'-biphenyl]-4-yl]ethyl]-1[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C \xrightarrow{NH} O \xrightarrow{Me} O O O$$

RN 845830-44-6 HCAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-[3,3'-difluoro-2'[[(trifluoromethyl)sulfonyl]amino][1,1'-biphenyl]-4-yl]ethyl]-1[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

RN 845830-50-4 HCAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-[2-fluoro-4-[1,2,3,4-tetrahydro-1[(trifluoromethyl)sulfonyl]-8-quinolinyl]phenyl]ethyl]-1[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 19:10:40 ON 14 MAR 2007)

1

FILE 'REGISTRY' ENTERED AT 19:10:46 ON 14 MAR 2007

L1 STRUCTURE UPLOADED

L2 15 S L1

L3 347 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 19:16:20 ON 14 MAR 2007

L4 7 S L3

L5 0 S L4 AND NEVILLE, A?/AU

L6 1 S L4 AND GOMEZ, R?/AU

=> s 14 not 16

L7 6 L4 NOT L6

=> s 17 and jolly, s?/au

277 JOLLY, S?/AU
L8 0 L7 AND JOLLY, S?/AU

=> s 17 and lim, j?/au

4025 LIM, J?/AU

L9 0 L7 AND LIM, J?/AU

=> s 17 and su, d?/au

1801 SU, D?/AU

L10 2 L7 AND SU, D?/AU

 \Rightarrow d 110, ibib abs hitstr, 1-2

L10 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2003:633647 HCAPLUS

DOCUMENT NUMBER:

139:179895

TITLE:

Preparation of N-biphenylmethyl

cycloalkanecarboxamides as bradykinin antagonists for treatment of conditions associated with the bradykinin

B1 pathway.

INVENTOR(S):

Wood, Michael R.; Anthony, Neville J.; Bock, Mark G.;

Feng, Dong-Mei; Kuduk, Scott D.; Su, Dai-Shi

; Wai, Jenny Miu-Chun

PATENT ASSIGNEE(S):

Merck & Co., Inc., USA PCT Int. Appl., 89 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE			
CO, CR, CU, GM, HR, HU, LT, LU, LV, PT, RO, RU, UG, US, UZ, RW: GH, GM, KE, KG, KZ, MD,	CZ, DE, DK, DM, ID, IL, IN, IS, MA, MD, MG, MK, SC, SD, SE, SG, VC, VN, YU, ZA, LS, MW, MZ, SD, RU, TJ, TM, AT,	SL, SZ, TZ, UG, ZM, BE, BG, CH, CY, CZ,	GB, GD, GE, GH, LC, LK, LR, LS, NZ, OM, PH, PL, TR, TT, TZ, UA, ZW, AM, AZ, BY, DE, DK, EE, ES,			
	CI, CM, GA, GN, A1 20031127 B2 20050719 A1 20030814 A1 20030902 A 20041207	CA 2003-2474373 AU 2003-216169 BR 2003-7508	SN, TD, TG 20030130 20030204 20030204 20030204			
EP 1501787 EP 1501787 R: AT, BE, CH, IE, SI, LT, US 2005084463 JP 2005517006 CN 1630633 AT 309202 ES 2250899 NZ 534062	LV, FI, RO, MK, A1 20050421 T 20050609 A 20050622 T 20051115 T3 20060416 A 20060630	GB, GR, IT, LI, LU, CY, AL, TR, BG, CZ, US 2003-503501 JP 2003-565952 CN 2003-803560 AT 2003-737624 ES 2003-3737624 NZ 2003-534062	EE, HU, SK 20030204 20030204 20030204 20030204 20030204 20030204			
IN 2004CN01753 NO 2004003739 PRIORITY APPLN. INFO.:	A 20060224 A 20041029 MARPAT 139:1798	US 2002-355062P US 2002-410172P WO 2003-US3338	W 20030204			
	10354	674 = ODP				
Updated Search	10/503501	~ 00r				

Title compds. [I; R1, R2 = H, alkyl; R3 = H, alkyl, haloalkyl; R31 = AΒ alkyl, haloalkyl; R4, R41 = H, halo, (substituted) alkyl; R4R41 = atoms to form (substituted) methylene; R5 = alkynyl, (substituted) alkyl, alkenyl, cycloalkyl, ar(alkyl), heterocyclyl(alkyl), etc.; R6 = cycloalkyl, halo, cyano, NO2, (substituted) alkyl, alkenyl, amino, acylamino, heterocyclyl, acyl, etc.; R61, R62 = H, R6; R7, R71 = H, halo, cyano, NO2, alkyl, haloalkyl, amino, CO2H, etc.; m = 0, 1], were prepared for treatment of pain and inflammation (no data). Thus, tert-Bu (1R)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethylcarbamate (preparation given), Me 2-fluoro-6-iodobenzoate, K2CO3, tri-o-tolylphosphine, and palladium acetate were heated at 90° for 18 h in THF/H2O to provide Me 4'-[(1R)-1-[(tert-butoxycarbonyl)amino]ethyl]-3-fluoro-1,1'biphenylcarboxylate. This was treated with HCl in MeOH to give an amine hydrochloride. The above amine hydrochloride along with 1-[(tert-butoxycarbonyl)amino]cyclopropanecarboxylic acid, HOBt.H2O, triethylamine, and EDCI were stirred 16.5 h in THF to give 86% Me 4'-[(1R)-1-[[[1-[(tert-butoxycarbonyl)amino]cyclopropyl]carbonyl]amino]eth yl]-3-fluoro-1,1'-bibiphenyl-2-carboxylate. This was stirred with HCl in MeOH to give a solid amine hydrochloride. The above amine hydrochloride, trifluoropropionic acid, HOBt.H2O, triethylamine, and EDCI in THF/DMF were stirred 18 h to give 67% Me 3-fluoro-4'-[(1R)-1-[[[1-[(3,3,3trifluoropropanoyl)amino]cyclopropyl]carbonyl]amino]ethyl]-1,1'-bibiphenyl-2-carboxylate. 578727-64-7P 578727-65-8P 578727-66-9P IT 578727-67-0P 578727-68-1P 578727-69-2P 578727-70-5P 578727-71-6P 578727-72-7P 578727-73-8P 578727-75-0P 578727-77-2P 578727-78-3P 578727-81-8P 578727-85-2P 578727-87-4P 578727-90-9P 578727-92-1P 578727-94-3P 578727-95-4P 578727-96-5P 578727-97-6P 578727-98-7P 578727-99-8P 578728-00-4P 578728-02-6P 578728-03-7P. 578728-04-8P 578728-05-9P 578728-07-1P 578728-09-3P 578728-10-6P 578728-11-7P 578728-12-8P 578728-13-9P 578728-14-0P 578728-16-2P 578728-18-4P 578728-19-5P 578728-20-8P 578728-21-9P 578728-22-0P 578728-23-1P 578728-24-2P 578728-25-3P 578728-27-5P 578728-29-7P 578728-30-0P

578728-32-2P 578728-35-5P 578728-36-6P

```
578728-37-7P 578728-39-9P 578728-40-2P
     578728-41-3P 578728-44-6P 578728-46-8P
     578728-48-0P 578728-51-5P 578728-53-7P
     578728-55-9P 578728-56-0P 578728-57-1P
     578728-58-2P 578728-59-3P 578728-60-6P
     578728-61-7P 578728-62-8P 578728-63-9P
     578728-64-0P 578728-65-1P 578728-66-2P
     578728-68-4P 578728-70-8P 578728-71-9P
     578728-72-0P 578728-73-1P 578728-75-3P
     578728-76-4P 578728-77-5P 578728-78-6P
     578728-79-7P 578728-84-4P 578728-86-6P
     578728-87-7P 578728-88-8P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
        (claimed compound; preparation of biphenylmethyl cycloalkanecarboxamides as
        bradykinin antagonists for treatment of conditions associated with
        bradykinin B1 pathway)
     578727-64-7 HCAPLUS
RN
     [1,1'-Biphenyl]-2-carboxylic acid, 3-fluoro-4'-[(1R)-1-[[[1-[(3,3,3-
CN
     trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl
     ester (9CI) (CA INDEX NAME)
```

Absolute stereochemistry.

RN 578727-65-8 HCAPLUS

(I,1'-Biphenyl]-2-carboxamide, 3-fluoro-N-methoxy-4'-[(1R)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

RN 578727-66-9 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3-fluoro-4'-[1-methyl-1-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester
(9CI) (CA INDEX NAME)

RN 578727-67-0 HCAPLUS
CN Cyclopropanecarboxamide, N-[(lR)-1-[3,3'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-68-1 HCAPLUS

[1,1'-Biphenyl]-2-carboxylic acid, 3-chloro-3'-fluoro-4'-[(1R)-1-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester

(9CI) (CA INDEX NAME)

RN 578727-69-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3,3'-difluoro-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-70-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1R)-1-[[[1-[(cyanoacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-fluoro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-72-7 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3-chloro-4'-[(1R)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-73-8 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578727-75-0 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[1-[[[1[(cyanoacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3,3'-difluoro-,

methyl ester (9CI) (CA INDEX NAME)

RN 578727-77-2 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[(1S)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$

$$NH$$

$$O$$

$$Me$$

$$O$$

$$O$$

$$Me$$

RN 578727-78-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[(1R)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-81-8 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[(1R)-1-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-85-2 HCAPLUS

[1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[(1S)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-87-4 HCAPLUS

Absolute stereochemistry.

Absolute stereochemistry.

$$\begin{array}{c|c} F \\ \hline \\ F \\ \hline \\ C1 \\ \hline \\ O \\ \hline \\ NH \\ O \\ \hline \\ Me \\ \hline \\ O \\ \hline \\ O \\ O \\ Me \\ \\ \end{array}$$

RN 578727-94-3 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3-chloro-4'-[(1R)-1-[[[1[(chlorodifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3'-fluoro-,
methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.

RN 578727-96-5 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[(1R)-1-[[[1[(2,2,3,3,3-pentafluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl
]-, methyl ester (9CI) (CA INDEX NAME)

RN 578727-97-6 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3-chloro-4'-[(1R)-1-[[[1[(difluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3'-fluoro-,
methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-98-7 HCAPLUS
CN Cyclopropanecarboxamide, 1-(acetylamino)-N-[(1R)-1-[3'-fluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)

RN 578727-99-8 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(cyanoacetyl)amino]-N-[(1R)-1-[3'-fluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-00-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3'-fluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-02-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1S)-1-[3,3'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)

RN 578728-03-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3,3'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-04-8 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(cyanoacetyl)amino]-N-[1-[3,3'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)

RN 578728-05-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[1-[3,3'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]-(9CI) (CA INDEX NAME)

RN 578728-07-1 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(chlorodifluoroacetyl)amino]-N-[(1R)-1-[3,3'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-09-3 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(difluoroacetyl)amino]-N-[(1R)-1-[3,3'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-(9CI) (CA INDEX NAME)

RN 578728-10-6 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(cyanoacetyl)amino]-N-[(1R)-1-[3'-fluoro-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-11-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3'-fluoro-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]-(9CI) (CA INDEX NAME)

RN 578728-12-8 HCAPLUS
CN Cyclopropanecarboxamide, 1-[(cyanoacety1)amino]-N-[(1R)-1-[3'-fluoro-2'-(1-methyl-1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-13-9 HCAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-[3'-fluoro-2'-(1-methyl-1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]-(9CI) (CA INDEX NAME)

RN 578728-14-0 HCAPLUS

CN Cyclopropanecarboxamide, 1-(acetylamino)-N-[(1R)-1-[3'-fluoro-2'-(1-methyl-1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-16-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[1-[3,3'-difluoro-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]-(9CI) (CA INDEX NAME)

$$F_{3}C-CH_{2}-C-NH$$

$$O$$

$$Me$$

$$N=N$$

$$N=N$$

RN 578728-18-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1S)-1-[3,3'-difluoro-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-19-5 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(chlorodifluoroacetyl)amino]-N-[(1R)-1-[3,3'-difluoro-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-20-8 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(difluoroacetyl)amino]-N-[(1R)-1-[3,3'-difluoro-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)

RN 578728-21-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-(2'-cyano-3'-fluoro[1,1'-biphenyl]-4-yl)ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$

$$NH$$

$$O$$

$$Me$$

$$CN$$

$$F_{3}C$$

RN 578728-22-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[2'-(difluoromethoxy)[1,1'-biphenyl]-4-yl]ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-23-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-4-

Updated Search

yl]ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]- (9CI) (CA INDEX NAME) Absolute stereochemistry.

$$F_3C$$
 NH
 O
 Me
 CF_3

578728-24-2 HCAPLUS RN

Cyclopropanecarboxamide, N-[(1R)-1-[3'-fluoro-2'-(trifluoromethyl)[1,1'-CN biphenyl]-4-yl]ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$
 NH
 O
 Me
 CF_{3}

RN 578728-25-3 HCAPLUS

Cyclopropanecarboxamide, N-[(1R)-1-(2',3'-dichloro[1,1'-biphenyl]-4-yl)ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)CN

$$F_3C$$
 NH
 O
 Me
 $C1$

RN 578728-27-5 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(cyanoacetyl)amino]-N-[(1R)-1-[3'-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-29-7 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(cyanoacetyl)amino]-N-[(1R)-1-(2',3'-dichloro[1,1'-biphenyl]-4-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c}
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\$$

RN 578728-30-0 HCAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[(1R)-1-[[[1-[(cyanoacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-2-fluoro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

RN 578728-32-2 HCAPLUS
[1,1'-Biphenyl]-2-carboxamide, 3-fluoro-N,N-dimethyl-4'-[(1R)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl](9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

RN 578728-35-5 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 3-fluoro-N-methyl-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-36-6 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 3-chloro-N-methyl-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

RN 578728-37-7 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 3-fluoro-N-methyl-4'-[(1R)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$

$$0$$

$$NHMe$$

$$NHMe$$

RN 578728-39-9 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-cyclopropyl-3-fluoro-4'-[(1R)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-40-2 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-cyclobutyl-3-fluoro-4'-[(1R)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-41-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3'-fluoro-2'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-44-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-fluoro-2'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

RN 578728-46-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5'-chloro-3-fluoro-2'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-48-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-fluoro-5'-methyl-2'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

RN 578728-51-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3,5'-difluoro-2'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-53-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-(3',5'-difluoro-2'-methoxy[1,1'-biphenyl]-4-yl)ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

RN 578728-55-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3,5'-difluoro-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-56-0 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 5-chloro-3'-fluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578728-57-1 HCAPLUS CN [1,1'-Biphenyl]-2-carboxylic acid, 5-chloro-4'-[(1R)-1-[[[1-

[(chlorodifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3'-fluoro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} & & & & \\ & & & \\ \hline F & & & \\ \hline C1 & & & \\ \hline O & & \\ \hline NH & & & \\ \hline O & & \\ \hline Me & & \\ \hline \end{array}$$

RN 578728-58-2 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3'-fluoro-5-methyl-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578728-59-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1R)-1-[[[1-[(chlorodifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3'-fluoro-5-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} & & & \\ & & & \\ \hline F & & & \\ \hline C1 & & & \\ \hline O & & & \\ \hline NH & & & \\ \hline O & & \\ \hline Me & & \\ \hline \end{array}$$

RN 578728-60-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3,5'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

RN 578728-61-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5'-chloro-3-fluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-62-8 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(chlorodifluoroacetyl)amino]-N-[(1R)-1-[5'-chloro-3-fluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)

RN 578728-63-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-fluoro-5'-methyl-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-64-0 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(chlorodifluoroacetyl)amino]-N-[(1R)-1-[3-fluoro-5'-methyl-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)

RN 578728-65-1 HCAPLUS

[1,1'-Biphenyl]-2-carboxylic acid, 3',5-difluoro-4'-[(1R)-1-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester

(9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$
 NH
 O
 Me
 O
 O
 Me

RN 578728-68-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5'-chloro-3-fluoro-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-70-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-fluoro-5'-methyl-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

RN 578728-71-9 HCAPLUS [1,1'-Biphenyl]-2-carboxamide, 3-chloro-3'-fluoro-N-methyl-4'-[(1R)-1-[[[1-CN [(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]- (9CI) (CA

INDEX NAME)

Absolute stereochemistry.

578728-72-0 HCAPLUS RN

Carbamic acid, [3-chloro-3'-fluoro-4'-[(1R)-1-[[[1-CN [(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2yl]-, methyl ester (9CI) (CA INDEX NAME)

578728-73-1 HCAPLUS RN Carbamic acid, [3-chloro-3'-fluoro-4'-[(1R)-1-[[[1-CN [(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

578728-75-3 HCAPLUS RN Carbamic acid, [3,3'-difluoro-4'-[(1R)-1-[[[1-CN

[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl][1,1'-biphenyl]-2yl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C \xrightarrow{NH} \underset{O}{\overset{H}{\overset{}}} \underset{Me}{\overset{}} \underset{O}{\overset{}} \underset{O}{\overset{}}$$

578728-76-4 HCAPLUS

RN [1,1'-Biphenyl]-2-acetic acid, 3,3'-difluoro-4'-[(1R)-1-[[[1-CN [(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

$$F_{3}C \xrightarrow{NH} O \xrightarrow{Me} O O$$

RN 578728-77-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 3,3'-difluoro-N-methyl-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-78-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3'-chloro-3-fluoro-2'-(methoxymethyl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$

$$NH$$

$$O$$

$$Me$$

$$O$$

$$O$$

RN 578728-79-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-(3',5'-dichloro-2'-hydroxy[1,1'-biphenyl]-4-yl)ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_3C$$
 NH
 O
 Me
 O
 O

RN 578728-84-4 HCAPLUS
[1,1'-Biphenyl]-2-carboxylic acid, 3'-fluoro-6-methyl-4'-[(1R)-1-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester

Absolute stereochemistry.

(9CI) (CA INDEX NAME)

$$F_{3}C$$

$$NH$$

$$O$$

$$Me$$

$$Me$$

$$Me$$

RN 578728-86-6 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1R)-1-[[[1[(chlorodifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3'-fluoro-6methyl-, methyl ester (9CI) (CA INDEX NAME)

RN 578728-87-7 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3'-fluoro-3-methyl-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578728-88-8 HCAPLUS

CN

[1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1R)-1-[[[1-[(chlorodifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3'-fluoro-3methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} & & & & \\ & & & \\ \hline F & & & \\ \hline C1 & & \\ \hline O & & \\ \hline NH & & \\ O & & \\ \hline Me & & \\ \hline \end{array}$$

IT 578729-02-9P 578729-03-0P 578729-04-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biphenylmethyl cycloalkanecarboxamides as bradykinin antagonists for treatment of conditions associated with bradykinin B1 pathway)

RN 578729-02-9 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4-chloro-3'-fluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$

$$NH$$

$$O$$

$$Me$$

$$O$$

$$O$$

$$Me$$

RN 578729-03-0 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3'-fluoro-4-methyl-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578729-04-1 HCAPLUS

IT 578729-07-4P 578729-11-0P 578729-19-8P

578729-24-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of biphenylmethyl cycloalkanecarboxamides as bradykinin antagonists for treatment of conditions associated with bradykinin B1 pathway)

RN 578729-07-4 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1R)-1-[[[1-[[(1,1dimethylethoxy)carbonyl]amino]cyclopropyl]carbonyl]amino]ethyl]-3-fluoro-,
methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578729-11-0 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[1-[[[1-[[(1,1-dimethylethoxy)carbonyl]amino]cyclopropyl]carbonyl]amino]-1-methylethyl]-3-fluoro-, methyl ester (9CI) (CA INDEX NAME)

Updated Search

RN 578729-19-8 HCAPLUS

CN Carbamic acid, [1-[[[(1R)-1-[3,3'-difluoro-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]amino]carbonyl]cyclopropyl]-, \ 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578729-24-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3-fluoro-4'-[(1R)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$
 NH
 O
 Me
 $CO_{2}H$
 $F_{3}C$

REFERENCE COUNT:

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN

7

ACCESSION NUMBER:

2003:633358 HCAPLUS

DOCUMENT NUMBER:

139:179892

TITLE:

Preparation of N-biphenylmethyl

cycloalkanecarboxamides as bradykinin Bl. antagonists or inverse agonists useful in the treatment of pain

and inflammation

INVENTOR(S):

Wood, Michael R.; Anthony, Neville J.; Bock, Mark G.;

Feng, Dong-mei; Kuduk, Scott D.; Su, Dai-shi

; Wai, Jenny Miu-chun

PATENT ASSIGNEE(S):

Merck & Co., Inc., USA

· PCT Int. Appl., 72 pp. CODEN: PIXXD2 SOURCE:

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE
WO 2003065789 WO 2003065789	A2 20030814 A3 20040311	WO 2003-US5782	20030204
W: AE, AG, AL, CO, CR, CU, GM, HR, HU, LT, LU, LV, PT, RO, RU,	AM, AT, AU, AZ, BA CZ, DE, DK, DM, DZ ID, IL, IN, IS, JP MA, MD, MG, MK, MN SC, SD, SE, SG, SK	, EC, EE, ES, FI, G , KE, KG, KR, KZ, I , MW, MX, MZ, NO, I , SL, TJ, TM, TN, Y	GB, GD, GE, GH, LC, LK, LR, LS, NZ, OM, PH, PL,
RW: GH, GM, KE, KG, KZ, MD, FI, FR, GB, BJ, CF, CG,	VC, VN, YU, ZA, ZM LS, MW, MZ, SD, SL RU, TJ, TM, AT, BE GR, HU, IE, IT, LU CI, CM, GA, GN, GQ	, SZ, TZ, UG, ZM, 1 , BG, CH, CY, CZ, 1 , MC, NL, PT, SE, 1 , GW, ML, MR, NE, 1	DE, DK, EE, ES, SI, SK, TR, BF, SN, TD, TG
CA 2473778 AU 2003217728 EP 1476419	A1 20030814 A1 20030902 A2 20041117	CA 2003-2473778 AU 2003-217728 EP 2003-713689	20030204 20030204 20030204
EP 1476419 R: AT, BE, CH, IE, SI, LT, JP 2005516979 AT 316954 ES 2256727 US 2005085667 US 7091380 PRIORITY APPLN. INFO.: OTHER SOURCE(S): GI	B1 20060201 DE, DK, ES, FR, GB LV, FI, RO, MK, CY T 20050609 T 20060215 T3 20060716 A1 20050421 B2 20060815 MARPAT 139:179892	G, GR, IT, LI, LU, 17, AL, TR, BG, CZ, 19, 2003-565227 AT 2003-713689 ES 2003-3713689 US 2004-503502 US 2002-355062P US 2002-410775P WO 2003-US5782	NL, SE, MC, PT, EE, HU, SK 20030204 20030204 20040803 P 20020208 P 20020912 W 20030204
R41 NR1	10 %	503502	
NR2 R71	R6 .		

AB Title compds. [I; R1, R2 = H, alkyl; R4, R41 = H, halo, (substituted)

ΙT

```
alkyl; R5 = alkynyl, (substituted) alkyl, cycloalkyl, alkenyl,
aryl(alkyl), heterocyclyl(alkyl), etc.; R6 = halo, cyano, NO2, cycloalkyl,
(substituted) alkyl, alkenyl, amino, acylamino, heterocyclyl, etc.; R61,
R62 = H, R6; R7, R71 = H, halo, cyano, NO2, OH, CO2H, alkyl, haloalkyl,
etc.; with provisos], were prepared for treatment of pain and inflammation
(no data). Thus, a mixture of THF, H2O, K2CO3, Me 2-iodobenzoate,
4-cyanophenylboronic acid, and bis(tri-o-tolylphosphine)palladium(II)
chloride was refluxed 3.5 h, cooled to ambient temperature, and stirred
overnight to give Me 4'-cyano-1,1'-biphenyl-2-carboxylate. The latter in
2 M NH3 in MeOH with a 50% aqueous slurry of Raney Ni was stirred under H2 for
9 h to give a residue which was dissolved in Et20/Et0Ac prior to
introduction of HCl to give Me 4'-(aminomethyl)-1,1'-biphenyl-2-
carboxylate hydrochloride. To the free base of the above in THF was added
1-[(tert-butoxycarbonyl)amino]cyclopropanecarboxylic acid, Et3N, HOBt.H2O,
and EDCI and the mixture was stirred overnight to provide Me
4'-{[[[1-[(tert-butoxycarbonyl)amino]cyclopropyl]carbonyl]amino]methyl]-
1,1'-biphenyl-2-carboxylate. The latter was treated with HCl in
CH2Cl2/MeOH to give the deprotected amine which was treated with HOBt.H2O,
3,3,3-trifluoropropionic acid, Et3N, and EDCI in DMF to give 78% Me
4'-[[[[1-[(3,3,3-trifluoropropanoyl)amino]cyclopropyl]carbonyl]amino]methy
1]-1,1'-biphenyl-2-carboxylate.
578766-13-9P 578766-14-0P 578766-15-1P
578766-16-2P 578766-17-3P 578766-18-4P
578766-20-8P 578766-21-9P 578766-25-3P
578766-27-5P 578766-29-7P 578766-30-0P
578766-34-4P 578766-36-6P 578766-37-7P
578766-38-8P 578766-42-4P 578766-48-0P
578766-50-4P 578766-51-5P 578766-52-6P
578766-53-7P 578766-54-8P 578766-55-9P
578766-56-0P 578766-57-1P 578766-59-3P
578766-67-3P 578766-69-5P 578766-82-2P
578766-86-6P 578766-87-7P 578766-88-8P
578767-07-4P 578767-09-6P 578767-12-1P
578767-13-2P 578767-15-4P 578767-17-6P
578767-21-2P 578767-23-4P 578767-24-5P
578767-25-6P 578767-28-9P 578767-30-3P
578767-34-7P 578767-38-1P 578767-40-5P
578767-48-3P 578767-50-7P 578767-52-9P
578767-54-1P 578767-55-2P 578767-56-3P
578767-57-4P 578767-64-3P 578767-65-4P
578767-66-5P 578767-67-6P 578767-68-7P
578767-69-8P 578767-71-2P 578767-72-3P
578767-73-4P 578767-74-5P 578767-75-6P
578767-76-7P 578767-79-0P 578767-80-3P
578767-81-4P 578767-82-5P 578767-84-7P
578767-85-8P 578767-87-0P 578767-88-1P
578767-89-2P 578767-91-6P 578767-98-3P
578767-99-4P 578768-00-0P 578768-07-7P
578768-09-9P 578768-11-3P 578768-12-4P
578768-13-5P 578768-14-6P 578768-15-7P
578768-16-8P 578768-17-9P 578768-18-0P
578768-21-5P 578768-23-7P 578768-24-8P
578768-29-3P 578768-30-6P 578768-31-7P
578768-32-8P 578768-33-9P 578768-34-0P
578768-36-2P 578768-39-5P 578768-41-9P
578768-42-0P 578768-43-1P 578768-44-2P
578768-45-3P 578768-46-4P 578768-47-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
```

(Uses)

(preparation of N-biphenylmethyl cycloalkanecarboxamides as bradykinin Bl antagonists or inverse agonists useful in the treatment of pain and inflammation)

RN 578766-13-9 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-14-0 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[methyl(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-15-1 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[(1R,2S)-2-[(acetyloxy)methyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Updated Search

RN 578766-16-2 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[(1R,2R)-2-(hydroxymethyl)-1[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-,
methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 578766-17-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[1[(methoxyoxoacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester
(9CI) (CA INDEX NAME)

RN 578766-18-4 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(aminooxoacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-20-8 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(cyanoacetyl)amino]cyclopropy

l]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-21-9 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(2-hydroxy-1-oxobutyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-25-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(2-methyl-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-27-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(methoxyacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-29-7 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(2-thienylacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester
(9CI) (CA INDEX NAME)

RN 578766-30-0 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[[(3,4dimethoxyphenyl)acetyl]amino]cyclopropyl]carbonyl]amino]methyl]-, methyl
ester (9CI) (CA INDEX NAME)

RN 578766-34-4 HCAPLUS

(I,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(4-methoxy-1,4-dioxobutyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-36-6 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(phenylacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-38-8 HCAPLUS

(I,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(1-oxo-3-phenylpropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI)

(CA INDEX NAME)

RN 578766-48-0 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[[(phenylthio)acetyl]amino]cyc

lopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-50-4 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(phenoxyacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-51-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(3,3-dimethyl-1-oxobutyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-52-6 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(3-cyclopentyl-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-53-7 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[1-[(3-methoxy-1,3-dioxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-54-8 HCAPLUS
[1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)acetyl]amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-55-9 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(3-methoxy-1oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI)
(CA INDEX NAME)

RN 578766-56-0 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(1-oxo-4-pentynyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-57-1 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(ethoxyacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-59-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(3-nitro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-67-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(1H-pyrazol-1-ylacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-82-2 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(1H-imidazol-1-ylacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578766-86-6 HCAPLUS

(I,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[[(5-methyl-1H-pyrazol-1-yl)acetyl]amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ &$$

RN 578766-88-8 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[[1-oxo-3-(1H-1,2,4-triazol-1-yl)propyl]amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

RN 578767-07-4 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(2,2-dimethyl-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-09-6 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(trifluoroacetyl)amino]cyclop ropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-12-1 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-13-2 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(cyanoacetyl)amino]cyclopropy l]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-15-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3,3'-difluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)

RN 578767-17-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3-fluoro-2'-[(methylamino)sulfonyl][1,1'-biphenyl]-4-yl]methyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)

RN 578767-21-2 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3-chloro-3'-fluoro-4'-[[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-23-4 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,6-difluoro-4'-[[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-24-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3-fluoro-6-methyl-4'-[[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-25-6 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3-chloro-6-methyl-4'-[[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} O & & & \\ \hline \\ C-NH-CH_2 & & & \\ NH-C-CH_2-CF_3 & & & \\ \hline \\ O & & & \\ \end{array}$$

· RN 578767-28-9 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3'-chloro-3-fluoro-4'-[[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-30-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3-fluoro-4'-[[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-34-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3,3'-difluoro-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]-(9CI) (CA INDEX NAME)

$$F_{3}C-CH_{2}-C-NH$$

$$C-NH-CH_{2}$$

$$F$$

RN 578767-38-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3,3'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]-(9CI) (CA INDEX NAME)

$$F_3C-CH_2-C-NH N-O \\ C-NH-CH_2 \\ F$$

RN 578767-40-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(3,3'-difluoro-2'-methoxy[1,1'-biphenyl]-4-yl)methyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)

RN 578767-48-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-50-7 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(dichloroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-52-9 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[(1-oxo-2-propenyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-54-1 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[[(2E)-1-oxo-2-butenyl]amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 578767-55-2 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[(1-oxobutyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI)
(CA INDEX NAME)

RN 578767-56-3 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(difluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-57-4 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-(acetylamino)cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-65-4 HCAPLUS
CN Cyclopropanecarboxamide, N-[[3,3'-difluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

RN 578767-66-5 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(2,2-dichloro-1oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl
ester (9CI) (CA INDEX NAME)

RN 578767-67-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3,3'-difluoro-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

$$F_{3}C-C-NH$$

$$C-NH-CH_{2}$$

$$F$$

RN 578767-68-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(3,3'-difluoro-2'-methoxy[1,1'-biphenyl]-4-yl)methyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

RN 578767-69-8 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(dichloroacetyl)amino]-N-[[3,3'-difluoro-2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

RN 578767-71-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3,3'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

$$F_{3}C-C-NH \qquad N-O \\ C-NH-CH_{2} \\ O \qquad F$$

RN 578767-72-3 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(2,2-dichloro-1-oxopropyl)amino]-N-[[3,3'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(9CI) (CA INDEX NAME)

RN 578767-73-4 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(3-carboxy-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, 2-methyl ester (9CI) (CA INDEX NAME)

578767-74-5 HCAPLUS RN

[1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(chlorodifluoroacetyl)amino]c CN yclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

578767-75-6 HCAPLUS

RN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[[[(1,1-CN dimethylethoxy)carbonyl]amino]acetyl]amino]cyclopropyl]carbonyl]amino]meth yl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-76-7 HCAPLUS

[1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-{(aminoacetyl)amino]cyclopropy CN l]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-79-0 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[1-[[(acetylamino)acetyl]amino]cy clopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-80-3 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-.
[(hydroxyacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester
(9CI) (CA INDEX NAME)

RN 578767-81-4 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[[1,3-dioxo-3-(3-pyridinyl)propyl]amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & \\ & & & \\ & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

RN 578767-82-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3-chloro-3'-fluoro-4'-[[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-84-7 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(bromoacetyl)amino]cyclopropy l]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-85-8 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3',6-difluoro-4'-[[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester
(9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
 & F \\
 & C \\
 & C \\
 & NH \\
 & C \\
 & O \\
 & O$$

RN 578767-87-0 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[1-[[2-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]cyclopropyl]carbonyl]amin

o]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578767-89-2 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[[(2R)-2-(acetylamino)-1-oxopropyl]amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

RN 578767-91-6 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3'-fluoro-3-methyl-4'-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester
(9CI) (CA INDEX NAME)

RN 578767-98-3 HCAPLUS
CN Carbamic acid, [3,3'-difluoro-4'-[[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl][1,1'-biphenyl]-2-yl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-99-4 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[1-[(2,2-difluoro-4-hydroxy-1-oxobutyl)amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-00-0 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[[(dimethylamino)acetyl]amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-07-7 HCAPLUS

CN Carbamic acid, [[3,3'-difluoro-4'-[[[[1-[(trifluoroacetyl)-amino]cyclopropy l]carbonyl]amino]methyl][1,1'-biphenyl]-2-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-09-9 HCAPLUS

CN Carbamic acid, [[[3,3'-difluoro-4'-[[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl][1,1'-biphenyl]-2-yl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-11-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(1,3-dioxobutyl)amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & & & \\ & & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\$$

RN 578768-12-4 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[(3-methoxy-1,3-dioxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-13-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[(2,2,3,3,3-pentafluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-14-6 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 3,3'-dichloro-N-methyl-4'-[[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]- (9CI) (CA
INDEX NAME)

RN 578768-15-7 HCAPLUS

[1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[(2-hydroxy-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI)

(CA INDEX NAME)

RN 578768-16-8 HCAPLUS

[1,1'-Biphenyl]-2-carboxamide, 3,3'-difluoro-N-methyl-4'-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)

RN 578768-17-9 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[(3-hydroxy-1-oxobutyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-18-0 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[(3-hydroxy-2-methylene-1-oxobutyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-21-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 3,3'-difluoro-N,N-dimethyl-4'-[[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)

RN 578768-23-7 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 3,3'-difluoro-N-methyl-4'-[[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)

RN 578768-24-8 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 3,3'-difluoro-N-methoxy-4'-[[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)

RN 578768-29-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[(1R,2S)-2-(hydroxymethyl)-1[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-,
methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 578768-30-6 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[(1R,2S)-2-(chloromethyl)-1[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-,
methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 578768-31-7 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[2-methylene-1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-32-8 HCAPLUS

Relative stereochemistry.

RN 578768-33-9 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[(1R,2S)-2-[(methylthio)methyl]-1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Relative stereochemistry.

RN 578768-36-2 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3',5'-trifluoro-4'-[[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester
(9CI) (CA INDEX NAME)

RN 578768-39-5 HCAPLUS
CN Cyclopropanecarboxamide, N-[[3,5'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

$$F_{3}C-C-NH-CH_{2}$$

$$N=0$$

$$N=0$$

$$F$$

RN 578768-41-9 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3',5-difluoro-4'-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester
(9CI) (CA INDEX NAME)

RN 578768-42-0 HCAPLUS

[1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[1[(methylamino)oxoacetyl]amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-43-1 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[[(dimethylamino)oxoacetyl]amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-45-3 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[[[2-(methylsulfonyl)ethyl]amino]oxoacetyl]amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-47-5 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[[oxo[(2-phenylethyl)amino]acetyl]amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

CN [1,1'-Biphenyl]-2-carboxylic acid, 3-fluoro-4'-[(1R)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]- (9CI) (CA

INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$

$$O$$

$$NH$$

$$O$$

$$Me$$

$$CO_{2}H$$

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1R)-1-[[[1-[[(1,1-dimethylethoxy)carbonyl]amino]cyclopropyl]carbonyl]amino]ethyl]-3-fluoro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 578727-64-7P 578727-65-8P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of N-biphenylmethyl cycloalkanecarboxamides as bradykinin Bl antagonists or inverse agonists useful in the treatment of pain and inflammation)

RN 578727-64-7 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3-fluoro-4'-[(1R)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-65-8 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 3-fluoro-N-methoxy-4'-[(1R)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

$$F_{3}C$$

$$NH$$

$$O$$

$$Me$$

$$Me$$

$$O$$

$$N$$

$$H$$

$$O$$

$$Me$$

$$O$$

```
=> d his
     (FILE 'HOME' ENTERED AT 19:10:40 ON 14 MAR 2007)
     FILE 'REGISTRY' ENTERED AT 19:10:46 ON 14 MAR 2007
               STRUCTURE UPLOADED
L1
             15 S L1
L2
            347 S L1 FULL
L3
     FILE 'HCAPLUS' ENTERED AT 19:16:20 ON 14 MAR 2007
              7 S L3
L4
              0 S L4 AND NEVILLE, A?/AU
L5
              1 S L4 AND GOMEZ, R?/AU
L6
              6 S L4 NOT L6
L7
              0 S L7 AND JOLLY, S?/AU
^{18}
              0 S L7 AND LIM, J?/AU
L9
              2 S L7 AND SU, D?/AU
L10
=> s 17 not 110
L11
             4 L7 NOT L10
=> s 111 and anthony, n?/au
           135 ANTHONY, N?/AU
             O L11 AND ANTHONY, N?/AU
1.12
=> d lll, ibib abs hitstr, 1-4
L11 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN
                         2006:1343127 HCAPLUS
ACCESSION NUMBER:
                         146:220125
DOCUMENT NUMBER:
                         Development of Orally Bioavailable and CNS Penetrant
TITLE:
                         Biphenylaminocyclopropane Carboxamide Bradykinin Bl
                         Receptor Antagonists
                         Kuduk, Scott D.; Di Marco, Christina N.; Chang, Ronald
AUTHOR(S):
                         K.; Wood, Michael R.; Schirripa, Kathy M.; Kim, June
                         J.; Wai, Jenny M. C.; DiPardo, Robert M.; Murphy,
                         Kathy L.; Ransom, Richard W.; Harrell, C. Meacham;
                         Reiss, Duane R.; Holahan, Marie A.; Cook, Jacquelynn;
                         Hess, J. Fred; Sain, Nova; Urban, Mark O.; Tang,
                         Cuyue; Prueksaritanont, Thomayant; Pettibone, Douglas
                         J.; Bock, Mark G.
                         Departments of Medicinal Chemistry, Neuroscience Drug
CORPORATE SOURCE:
                         Discovery, Pain Research, and Drug Metabolism, Merck
                         Research Laboratories, West Point, PA, 19486, USA
                         Journal of Medicinal Chemistry (2007), 50(2), 272-282
SOURCE:
                         CODEN: JMCMAR; ISSN: 0022-2623
                         American Chemical Society
PUBLISHER:
                         Journal
DOCUMENT TYPE:
                         English
LANGUAGE:
     A series of biphenylaminocyclopropane carboxamide based bradykinin B1
     receptor antagonists has been developed that possesses good
     pharmacokinetic properties and is CNS penetrant. Discovery that the
     replacement of the trifluoropropionamide in the lead structure with
     polyhaloacetamides, particularly a trifluoroacetamide, significantly
     reduced P-glycoprotein mediated efflux for the series proved essential.
     One of these novel bradykinin Bl antagonists (13b) also exhibited suitable
     pharmacokinetic properties and efficient ex vivo receptor occupancy for
```

further development as a novel approach for the treatment of pain and inflammation.

IT 578727-67-0P 578727-68-1P 578727-69-2P 578727-81-8P 578727-90-9P 925215-11-8P

925215-12-9P 925215-13-0P 925215-14-1P

925215-15-2P 925215-16-3P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oral CNS penetrant biphenylaminocyclopropane carboxamide derivs. as bradykinin Bl receptor antagonists for treatment of pain and inflammation)

RN 578727-67-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3,3'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-68-1 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3-chloro-3'-fluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-69-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3,3'-difluoro-2'-(2-methyl-2H-tetrazol-

Updated Search

5-yl)[1,1'-biphenyl]-4-yl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-81-8 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-90-9 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3'-fluoro-4'-[(1R)-1-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester
(9CI) (CA INDEX NAME)

$$F_{3}C \longrightarrow NH \longrightarrow Me \longrightarrow OMe$$

RN 925215-11-8 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3-chloro-3'-fluoro-4'-[(1R)-1-[[[1-[(2,2,2-trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN 925215-12-9 HCAPLUS CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

RN 925215-13-0 HCAPLUS Cyclopropanecarboxamide, N-[(1R)-1-[3'-chloro-3-fluoro-2'-(2-methyl-2H- $^{\circ}$

Updated Search

tetrazol-5-yl) [1,1'-biphenyl]-4-yl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino] (CA INDEX NAME)

Absolute stereochemistry.

RN 925215-14-1 HCAPLUS CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

RN 925215-15-2 HCAPLUS CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[(1R)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

$$F_{3}C$$

$$NH$$

$$O$$

$$Me$$

$$O$$

$$O$$

$$Me$$

```
IT
     578727-87-4P 578727-92-1P 578727-95-4P
     578727-96-5P 578767-48-3P 578767-50-7P
     578767-56-3P 578767-57-4P 578767-66-5P
     578767-74-5P 578768-13-5P 925214-98-8P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
        (preparation of oral CNS penetrant biphenylaminocyclopropane carboxamide
        derivs. as bradykinin B1 receptor antagonists for treatment of pain and
        inflammation)
     578727-87-4 HCAPLUS
RN
     [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1R)-1-[[[1-
CN
     (acetylamino)cyclopropyl]carbonyl]amino]ethyl]-3,3'-difluoro-, methyl
     ester (9CI)
                 (CA INDEX NAME)
```

Absolute stereochemistry.

RN 578727-92-1 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1R)-1-[[[1[(chlorodifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3,3'difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578727-95-4 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1R)-1-[[[1-[(difluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578727-96-5 HCAPLUS

[1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[(1R)-1-[[[1-[(2,2,3,3,3-pentafluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl
]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 578767-48-3 HCAPLUS

Updated Search

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-50-7 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(dichloroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-56-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(difluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & & \\ & &$$

RN 578767-57-4 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-(acetylamino)cyclopropyl]carbo nyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-66-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[1-[(2,2-dichloro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-74-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(chlorodifluoroacetyl)amino]c yclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 578768-13-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[[[[1-[(2,2,3,3,3-pentafluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 925214-98-8 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4!-[[[[1-[(2-chloro-2-fluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3,3'-difluoro-, methyl ester (CA INDEX NAME)

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'-[(1S)-1-[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 578767-12-1 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3'-difluoro-4'~[[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

IT 925215-17-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of oral CNS penetrant biphenylaminocyclopropane carboxamide derivs. as bradykinin B1 receptor antagonists for treatment of pain and inflammation)

RN 925215-17-4 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3-chloro-4'-[(1R)-1-[[[1-[[(1,1-dimethylethoxy)carbonyl]amino]cyclopropyl]carbonyl]amino]ethyl]-3'-fluoro-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN

28

ACCESSION NUMBER: 2006:83153 HCAPLUS

DOCUMENT NUMBER:

144:304953

TITLE:

Cyclopropylamino Acid Amide as a Pharmacophoric Replacement for 2,3-Diaminopyridine. Application to the Design of Novel Bradykinin Bl Receptor Antagonists Wood, Michael R.; Schirripa, Kathy M.; Kim, June J.; Wan, Bang-Lin; Murphy, Kathy L.; Ransom, Richard W.; Chang, Raymond S. L.; Tang, Cuyue; Prueksaritanont,

Thomayant; Detwiler, Theodore J.; Hettrick, Lisa A.;

AUTHOR(S):

Updated Search

Landis, Elizabeth R.; Leonard, Yvonne M.; Krueger, Julie A.; Lewis, Sidney D.; Pettibone, Douglas J.;

Freidinger, Roger M.; Bock, Mark G.

CORPORATE SOURCE: Departments of Medicinal Chemistry, Neuroscience, Drug

Metabolism, and Chemical Biology, Merck Research

Laboratories, West Point, PA, 19486, USA

SOURCE: Journal of Medicinal Chemistry (2006), 49(4),

1231-1234

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 144:304953

AB Antagonism of the bradykinin Bl receptor represents a potential treatment for chronic pain and inflammation. Novel antagonists were designed that display low-nanomolar affinity for the human bradykinin Bl receptor and good bioavailability in the rat.


IT 578766-13-9P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(cyclopropylamino acid amide as pharmacophore for diaminopyridine: bradykinin receptor antagonists preparation for potential treatment of chronic pain and inflammation)

RN 578766-13-9 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1004708 HCAPLUS

DOCUMENT NUMBER: 143:306182

TITLE: Preparation of 1-aminocyclopropane-1-carboxamide

derivatives as bradykinin B1 antagonists Bock, Mark G.; Feng, Dong-Mei; Kuduk, Scott

PATENT ASSIGNEE(S): Merck & Co., Inc., USA SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

INVENTOR(S):

PATENT NO.	KIND DATE	APPLICATION NO.	DATE
	A2 20050915 A3 20051124	WO 2005-US6230	20050225
W: AE, AG, F CN, CO, C GE, GH, C LK, LR, I NO, NZ, C SY, TJ, T RW: BW, GH, C AZ, BY, F	L, AM, AT, AU, AZ, R, CU, CZ, DE, DK, M, HR, HU, ID, IL, S, LT, LU, LV, MA, M, PG, PH, PL, PT, M, TN, TR, TT, TZ, M, KE, LS, MW, MZ, G, KZ, MD, RU, TJ,	BA, BB, BG, BR, BW, DM, DZ, EC, EE, EG, IN, IS, JP, KE, KG, MD, MG, MK, MN, MW, RO, RU, SC, SD, SE, UA, UG, US, UZ, VC, NA, SD, SL, SZ, TZ, TM, AT, BE, BG, CH,	ES, FI, GB, GD, KP, KR, KZ, LC, MX, MZ, NA, NI, SG, SK, SL, SM, VN, YU, ZA, ZM, ZW UG, ZM, ZW, AM, CY, CZ, DE, DK,
RO, SE, S MR, NE, S	I, SK, TR, BF, BJ, N, TD, TG	IE, IS, IT, LT, LU, CF, CG, CI, CM, GA,	GN, GQ, GW, ML,
		AU 2005-219836	
EP 1723143	A2 20061122	CA 2005-2557858 EP 2005-714101	20050225
IS, IT, I	I, LT, LU, MC, NL,	DK, EE, ES, FI, FR, PL, PT, RO, SE, SI,	SK, TR, LV
CN 1926136 PRIORITY APPLN. INFO.:		CN 2005-80006734 US 2004-549379P	P 20040302
OTHER SOURCE(S):	MARPAT 143:3061	WO 2005-US6230 82	W 20050225

AB Title compds. I [wherein Rla, Rlb, Rlc = H or F; R2 = H or Cl; R3 = Cl or

F; R4 = (un)substituted (cyclo)alkyl, aryl or heterocycle, or pharmaceutically acceptable salts thereof) were prepared as antagonists or inverse agonists of bradykinin receptors, especially as antagonists of bradykinin receptor B1. For instance, II was synthesized by acylation of dihydrochloride salt of the corresponding cyclopropanamine with 5-methylisoxazole-3-carbonyl chloride in the presence of DIPEA. I exhibited affinity for the B1 receptor with IC50 values of $<5\,\mu\text{M}$. Therefore, I and their pharmaceutical compns. (examples given) are useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

associated with the bradykinin BI pathwa 1T 864641-51-0P 864641-56-5P 864641-76-9P 864641-88-3P 864641-94-1P 864642-05-7P 864642-20-6P 864642-32-0P 864642-35-3P 864642-37-5P 864642-60-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminocyclopropanecarboxamide derivs. as bradykinin Bl antagonists)

RN 864641-51-0 HCAPLUS

CN Cyclopropanecarboxamide, 1-(acetylamino)-N-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 864641-56-5 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(cyanoacetyl)amino]-N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]- (9CI) (CA INDEX NAME)

RN 864641-76-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[3-chloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 864641-88-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(1-oxopropyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 864641-94-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]-1[[(methylsulfonyl)acetyl]amino]- (9CI) (CA INDEX NAME)

RN 864642-05-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(3-chloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 864642-20-6 HCAPLUS

CN Cyclopropanecarboxamide, 1-(acetylamino)-N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 864642-32-0 HCAPLUS .

CN Cyclopropanecarboxamide, 1-[(chlorodifluoroacetyl)amino]-N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]- (9CI) (CA INDEX

Updated Search

NAME)

Absolute stereochemistry.

RN 864642-35-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(1-oxobutyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 864642-37-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(2-methyl-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)

RN 864642-60-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(difluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 864642-89-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminocyclopropanecarboxamide derivs. as bradykinin Bl antagonists)

RN 864642-89-7 HCAPLUS

CN Carbamic acid, [1-[[[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2004:203618 HCAPLUS

DOCUMENT NUMBER:

140:253570

TITLE:

Preparation of N-biarylmethylaminocycloalkanecarboxami

de as bradykinin B1 antagonists

INVENTOR(S):

Kuduk, Scott D.; Wood, Michael R.; Bock, Mark G.

PATENT ASSIGNEE(S):

Merck & Co., Inc., USA PCT Int. Appl., 59 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PAT						APPLICATION NO.					DATE						
WO.	2004	`_			Δ2 20040311			WO 2003-US26628					20030825				
	0 2004019868												20000020				
,,,	W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
1											EE,						
											KG,						
											MX,						
											SK,			TJ,	TM,	TN,	TR,
											ZA,						
	RW:										TZ,						
											CH,						
											NL,						
	0.405										GW,						
CA 2495914																	
								AU 2003-265674									
							BR 2003-13239 EP 2003-791763										
EP																	
	R:										IT,						P1,
QV.	1 (70	IE,	51,	LT,	ъ,	rт,	2005	MK,	CY,	AL,	TR,	, DB	C4,	EE,	пυ,	0030 20	025
CN 1678320			A 20051005			CN 2003-820293 JP 2004-532994				20030025							
JP	2005	2002	23 05		7.1		2005	1220		JP Z	004-	5323	74 11		2	0050	200
		2883	US		H.T		2003	1229		U\$ Z	005-	3239	T T		4	0030	200
	7163 2005	9015	20		D Z		2007	0110		NO 2	005-	1520			2	0050	323
PRIORIT					A		2003	0323			003-						
FRIORII	1 WEE	Τι.	TIVEO	• •							003-					0030	
OTHER SO	OURCE	(S):			MAR	PAT	140:	2535		2	005	0020		,			

```
* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
     Title compds. I [Het = pyridyl, pyrimidinyl, N-oxide thereof; R1-2 = H,
AB
     alkyl; R3a-3b = H, alkyl; R4a-4b = H, halo, alkyl, etc.; R5 = alkyl,
     cycloalkyl, alkynyl, alkenyl, etc.; R6a = alkyl, cycloalkyl, alkenyl,
     etc.; R6b-6c = H and not more than one of R6a-6c = heterocycle; R7a-7b =
     H, halo, CN, etc.; m = 0-3] are prepared For instance, 1-[((pyrimidin-5-
     yl)carbonyl)amino]cyclobutanecarboxylic acid (preparation given) is coupled to
     Me 2-[2-(aminomethyl)pyrimidin-5-yl]-6-fluorobenzoate (preparation given; DMF,
     HOBt, EDCI, Et3N) to give II. Compds. of the invention have affinity for the bradykinin Bl receptor at less than 5 \mu M . I are useful for the
     treatment of pain and inflammation.
     669066-20-0P, N-[[3-Chloro-5-[3-fluoro-2-(2-methyl-2H-tetrazol-5-
ΙT
     yl)phenyl]pyridin-2-yl]methyl]-1-[(trifluoroacetyl)amino]cyclopropanecarbo
     xamide 669066-34-6P, Methyl 2-fluoro-6-[5-fluoro-6-[[[1-
     [(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]pyridin-3-
     yl]benzoate 669066-47-1P, 1-[[(2,2,2-
     Trifluoroethyl)carbonyl]amino]-1-[[[[5-[2-(carbomethoxy)-3-(fluoro)phenyl]-
     3-fluoropyridin-2-yl]methyl]amino]carbonyl]cyclopropane
     669066-48-2P, 1-[[(Dichloromethyl)carbonyl]amino]-1-[[[[5-[2-
     (carbomethoxy)-3-(fluoro)phenyl]-3-fluoropyridin-2-
     yl]methyl]amino]carbonyl]cyclopropane 669066-49-3P,
     1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-(carbomethoxy)-3-
     (fluoro)phenyl]-3-chloropyridin-2-yl]methyl]amino]carbonyl]cyclopropane
     669066-50-6P, 1-[[(1,1-Dichloroethyl)carbonyl]amino]-1-[[[[5-[2-
     (carbomethoxy) -3-(fluoro) phenyl]-3-chloropyridin-2-
     yl]methyl]amino]carbonyl]cyclopropane 669066-51-7P
     669066-52-8P 669066-53-9P, 1-
     [[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-(carbomethoxy)-3-
     (chloro)phenyl]-3-chloropyridin-2-yl]methyl]amino]carbonyl]cyclopropane
     669066-54-0P, 1-[[(Difluoromethyl)carbonyl]amino]-1-[[[[5-[2-1]]]]
     (carbomethoxy) -3-(chloro) phenyl] -3-chloropyridin-2-
     yl]methyl]amino]carbonyl]cyclopropane 669066-55-1P
     (carbomethoxy)-3-(chloro)phenyl]-3-fluoropyridin-2-
     yl]methyl]amino]carbonyl]cyclopropane 669066-57-3P,
     1-[[(Dichlorofluoromethyl)carbonyl]amino]-1-[[[[5-[2-(carbomethoxy)-3-
     (chloro)phenyl]-3-fluoropyridin-2-yl]methyl]amino]carbonyl]cyclopropane
     669066-58-4P, 1-[[(Difluoromethyl)carbonyl]amino]-1-[[[[5-[2-
     (carbomethoxy) -3-(chloro) phenyl] -3-fluoropyridin-2-
     yl]methyl]amino]carbonyl]cyclopropane 669066-59-5P,
     1-[[[(Carbomethoxy)amino]carbonyl]amino]-1-[[[[5-[2-(carbomethoxy)-3-[]]]]]
     (chloro)phenyl]-3-chloropyridin-2-yl]methyl]amino]carbonyl]cyclopropane
     669066-60-8P, 1-[[[(Carbomethoxy)amino]carbonyl]amino]-1-[[[[5-[2-
     (carbomethoxy)-3-(chloro)phenyl]pyridin-2-yl]methyl]amino]carbonyl]cyclopr
     opane 669066-61-9P, 1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-
     [2-(carbomethoxy)-5-(chloro)phenyl]-3-chloropyridin-2-
     yl]methyl]amino]carbonyl]cyclopropane 669066-62-0P,
     1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-(carbomethoxy)-3-(chloro)-]]]]
     5-(chloro)phenyl]-3-chloropyridin-2-yl]methyl]amino]carbonyl]cyclopropane
     669066-63-1P, 1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-
     (carbomethoxy) -3-(chloro) -5-(chloro) phenyl] -3-fluoropyridin-2-
     yl]methyl]amino]carbonyl]cyclopropane 669066-64-2P,
     1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-(carbomethoxy)-3-(fluoro)-
```

```
5-(chloro)phenyl]-3-chloropyridin-2-yl]methyl]amino]carbonyl]cyclopropane
669066-65-3P, 1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-
(carbomethoxy) -3-(fluoro) -5-(chloro) phenyl] -3-fluoropyridin-2-
yl]methyl]amino]carbonyl]cyclopropane 669066-67-5P
669066-68-6P, 1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-(2-
methyl-2H-tetrazol-5-yl)-3-(fluoro)phenyl]-3-fluoropyridin-2-
yl]methyl]amino]carbonyl]cyclopropane 669066-69-7P
669066-70-0P, 1-[[(Difluoromethyl)carbonyl]amino]-1-[[[[5-[2-(2-
methyl-2H-tetrazol-5-yl)-3-(fluoro)phenyl]-3-fluoropyridin-2-
yl]methyl]amino]carbonyl]cyclopropane 669066-71-1P,
5-yl)-3-(fluoro)phenyl]-3-fluoropyridin-2-yl]methyl]amino]carbonyl]cyclopr
opane 669066-72-2P 669066-73-3P 669066-74-4P
, 1-[[(Methyl)carbonyl]amino]-1-[[[[5-[2-(2-methyl-2H-tetrazol-5-yl)-3-
(chloro)phenyl]-3-chloropyridin-2-yl]methyl]amino]carbonyl]cyclopropane
669066-75-5P 669066-76-6P 669066-77-7P,
1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-methyl-2H-tetrazol-5-(2-m
y1)-3-(chloro)-5-(chloro)phenyl]-3-fluoropyridin-2-
yl]methyl]amino]carbonyl]cyclopropane 669066-78-8P
669066-79-9P 669066-80-2P, 1-
[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-(2-methyl-2H-tetrazol-5-yl)-1]]]]]
3-(fluoro)-5-(chloro)phenyl]-3-fluoropyridin-2-
yl]methyl]amino]carbonyl]cyclopropane 669066-81-3P,
1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-(5-methyl-1,2,4-oxadiazol-1]]]]]]
3-y1)-5-(chloro)pheny1]-3-chloropyridin-2-y1]methyl]amino]carbony1]cyclopr
opane 669066-82-4P, 1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-
[2-(5-methyl-1,2,4-oxadiazol-3-yl)-3-(chloro)-5-(chloro)phenyl]-3-
chloropyridin-2-yl]methyl]amino]carbonyl]cyclopropane 669066-83-5P
 , 1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-(5-methyl-1,2,4-
oxadiazol-3-yl)-3-(chloro)-5-(chloro)phenyl]-3-fluoropyridin-2-
yl]methyl]amino]carbonyl]cyclopropane 669066-85-7P,
1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-[2-fluoro-2-
 (fluoromethyl)ethoxy]-3-(chloro)-5-(chloro)phenyl]-3-chloropyridin-2-
yl]methyl]amino]carbonyl]cyclopropane 669066-86-8P,
 1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-[2-fluoro-2-
 (fluoromethyl)ethoxy]-3-(chloro)-5-(chloro)phenyl]-3-pyridin-2-
 yl]methyl]amino]carbonyl]cyclopropane 669066-87-9P,
 1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[[5-[2-[(carbomethoxy)oxy]-3-
 (fluoro)phenyl]-3-fluoropyridin-2-yl]methyl]amino]carbonyl]cyclopropane
 669066-88-0P 669066-99-3P 669067-00-9P
 669067-01-0P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-
 [2-(carbomethoxy)-3-(chloro)phenyl]-3-chloropyridin-2-
 yl]ethyl]amino]carbonyl]cyclopropane 669067-02-1P,
 (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-[2-(3-methyl-1,2,4-1]]]]]]
 oxadiazol-5-yl)-3-(fluoro)phenyl]-3-chloropyridin-2-
 yl]ethyl]amino]carbonyl]cyclopropane 669067-03-2P,
  (R) -1 - [[(Trifluoromethyl) carbonyl] amino] -1 - [[[1 - [5 - [2 - (trifluoromethyl) - 3 - [1 - [2 - (trifluoromethyl) - 3 - (trifluoromethyl) - 3 - [2 - (trifluoromethyl) - 3 - (trifluoromethyl) - (trifluoromethyl) - (trifluoromethyl) - (trifluoromethyl) - (trifluoromethyl) - (trifluoromethyl) - (trifluoromethyl
 (fluoro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
 669067-04-3P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-1]]669067-04-3P]]
 [2-(trifluoromethyl)-3-(fluoro)phenyl]pyridin-2-
 yl]ethyl]amino]carbonyl]cyclopropane 669067-05-4P,
 (chloro)phenyl]pyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
 669067-06-5P, (R) -1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-1]]669067-06-5P]]
 \label{lem:condition} \hbox{\tt [2-(5-methyl-1,2,4-oxadiazol-3-yl)-5-(chloro)phenyl]-3-chloropyridin-2-}
yl]ethyl]amino]carbonyl]cyclopropane 669067-07-6P,
  (R) -1 - [[(Trifluoromethyl) carbonyl] amino] -1 - [[[1 - [5 - [2 - (trifluoromethyl) - 3 - [1 - [2 - (trifluoromethyl) - 3 - (trifluoromethyl) - 3 - [2 - (trifluoromethyl) - 3 - (trifluoromethyl) - (trifluoromethyl) - (trifluoromethyl) - 3 - (trifluoromethyl) - (trifluorome
  (fluoro)phenyl]-3-fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
 669067-08-7P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-^{\circ}]
```

```
[2-(carbomethoxy)-3-(chloro)phenyl]-3-fluoropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-09-8P,
 (R)-1-[[(Difluoromethyl)carbonyl]amino]-1-[[[1-[5-[2-(carbomethoxy)-3-[]]]]]
 (chloro)phenyl]-3-fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
669067-10-1P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-
 [2-(trifluoromethyl)-3-(chloro)phenyl]-3-fluoropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-11-2P,
  (R) -1 - [[(Trifluoromethyl) carbonyl] amino] -1 - [[[1 - [5 - [2 - (difluoromethoxy) - 3 - [2 - (difluoromethyl) carbonyl]]] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] [[[1 - [5 - [2 - (difluoromethoxy) - 3 - [2 - (difluoromethyl) carbonyl]]] ] ] ] ] ] ] ] ] ] [[[1 - [5 - [2 - (difluoromethoxy) - 3 - [2 - (difluoromethyl) carbonyl]]] ] ] ] ] ] ] ] ] ] ] [[[1 - [5 - [2 - (difluoromethoxy) - 3 - [2 - (difluoromethyl) carbonyl]]] ] ] ] ] ] [[[1 - [5 - [2 - (difluoromethoxy) - 3 - [2 - (difluoromethoxy) - [2 - (difluoromethoxy) - 3 - [2 - (difluoromethoxy) - 2 - (difluoromethoxy) - [2 - (difluoromethoxy) - (difluoromethoxy) - [2 -
 (fluoro)phenyl]-3-fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
 669067-12-3P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-^{-}]
 [2-(trifluoromethyl)-5-(chloro)phenyl]-3-fluoropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-13-4P,
 (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-[2-(5-methyl-1,2,4-methyl-1,2,4-methyl-1,2,4-methyl-1,2,4-methyl-1,2,4-methyl-1,2,4-methyl-1,2,4-methyl-1,2,4-methyl-1,2,4-methyl-1,2,4-methyl-1,2,4-methyl-1,2,4-methyl-1,2,4-methyl-1,2,4-methyl-1,2,4-methyl-1,2,4-methyl-1,2,4-methyl-1,2,4-methyl-1,2,4-methyl-1,2,4-methyl-1,2,4-methyl-1,2,4-methyl-1,2,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methyl-1,4-methy
oxadiazol-3-yl)-3-(chloro)-5-(chloro)phenyl]-3-fluoropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-15-6P,
 (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-[2-(2,2,2-1)]]amino]-1-[[[1-[5-[2-(2,2,2-1)]]amino]-1-[[[1-[5-[2-(2,2,2-1)]]amino]-1-[[[1-[5-[2-(2,2,2-1)]]amino]-1-[[[1-[5-[2-(2,2,2-1)]]amino]-1-[[1-[5-[2-(2,2,2-1)]]amino]-1-[[1-[5-[2-(2,2,2-1)]]amino]-1-[[1-[5-[2-(2,2,2-1)]]amino]-1-[[1-[5-[2-(2,2,2-1)]]amino]-1-[[1-[5-[2-(2,2,2-1)]]amino]-1-[1-[2-[2-(2,2,2-1)]]amino]-1-[1-[2-[2-(2,2,2-1)]]amino]-1-[1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)]]amino]-1-[2-[2-(2,2,2-1)][amino]-1-[2-[2-(2,2,2-1)][amino]-1-[2-(2-(2,2,2-1)][amino]-1-[2-(2-(2,2,2-1)][amino]-1-[2-(2-(2,2,2-1)][amino]-1-[2-(2-(2,2,2-1)][amino]-1-[2-(2-(2,2,2-1)][amino]-1-[2-(2-(2,2,2-1)][amino]-1-[2-(2-(2,2,2-1)][amino]-1-[2-(2-(2,2,2-1)][amino]-1-[2-(2-(2,2,2-1)][amino]-1-[2-(2-(2,2,2-1)][amino]-1-[2-(2-(2,2,2-1)][amino]-1-[2-(2-(2,2,2-1)][amino]-1-[2-(2-(2,2,2-1)][amino]-1-[2-(2-(2,2,2-1)][amino]-1-[2-(2-(2,2,2-1)][amino]-1-[2-(2-(2,2,2-1)][amino]-1-[2-(2-(2,2,2-1)][amino]-1-[2-(2-(2,2,2-1)][amino]-1-[2-(2-(2,2,2-1)][amino]
 trifluoroethoxy)-3-(fluoro)phenyl]-3-fluoropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-16-7P,
  (chloro)phenyl]-3-fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
 669067-17-8P 669067-18-9P 669067-19-0P,
  (R) -1 - [[(Trifluoromethyl) carbonyl] amino] -1 - [[[1 - [5 - [2 - (2, 2 - difluoroethoxy) - (2, 2 - difluoroethoxy) - (2, 2 - difluoroethoxy) - (3, 2 - difluoroethoxy) - (4, 3 - difluoroethoxy) -
 3-(fluoro)phenyl]-3-fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
 669067-20-3P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-^{\circ}]
 [2-(2-methyl-2H-tetrazol-5-yl)-3-(chloro)-5-(chloro)phenyl]-3-
 fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-21-4P
          tetrazol-5-yl)-5-(chloro)phenyl]-3-fluoropyridin-2-
 yl]ethyl]amino]carbonyl]cyclopropane 669067-22-5P,
  (R) -1 - [[(Trifluoromethyl) carbonyl] amino] -1 - [[[1 - [5 - [2 - (carboethoxy) - 3 - [2 - (carboethoxy) - 2 - [2 - 
  (chloro)phenyl]-3-fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
 669067-23-6P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-
 [2-(2-methyl-2H-tetrazol-5-yl)-3-(fluoro)-5-(chloro)phenyl]-3-
 fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-24-7P
 , (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-[2-(carbomethoxy)-3-[-1-[[[1-[5-[2-(carbomethoxy)-3-[-1-[-1]]]]]
 (fluoro)-5-(chloro)phenyl]-3-fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclo
 propane 669067-25-8P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-
 [[[1-[5-[2-(2-fluoroethoxycarbonyl)-3-(chloro)phenyl]-3-fluoropyridin-2-
 yl]ethyl]amino]carbonyl]cyclopropane 669067-26-9P
 669067-27-0P, (R)-1-[[(Difluoromethyl)carbonyl]amino]-1-[[[1-[5-[2-1]]
  (carbomethoxy) -3-(chloro) -5-(chloro) phenyl] -3-fluoropyridin-2-
 yl]ethyl]amino]carbonyl]cyclopropane 669067-28-1P,
  (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-[2-(carboethoxy)-3-
  (fluoro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclo
 propane 669067-29-2P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-
 [[[1-[5-[2-(carboethoxy)-3-(chloro)-5-(chloro)phenyl]-3-fluoropyridin-2-
 yl]ethyl]amino]carbonyl]cyclopropane 669067-30-5P,
  fluoroethoxycarbonyl)-3-(fluoro)-5-(chloro)phenyl]-3-fluoropyridin-2-
 yl]ethyl]amino]carbonyl]cyclopropane 669067-31-6P,
   (R) -1 - [\ [\ (Trifluoromethyl)\ carbonyl\ ]\ amino\ ] -1 - [\ [\ [1-[5-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbomethoxy)-3-[2-(carbom
  (fluoro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclo
 propane 669067-32-7P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-
  [[[1-[5-[2-(2-fluoroethoxycarbonyl)-3-(fluoro)-5-(chloro)phenyl]-3-
 chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-33-8P
    (R)-1-[[(Methyl)carbonyl]amino]-1-[[[1-[5-[2-(2-methyl-2H-tetrazol-5-yl)-
 3-(fluoro)-5-(chloro)phenyl]-3-chloropyridin-2-
 yl]ethyl]amino]carbonyl]cyclopropane 669067-34-9P,
  (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-[2-(carboethoxy)-3-(R)-[-[-1](R)-1-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R)-[-1](R
```

```
(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
669067-35-0P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-^{\circ}]
[2-(carboethoxy)-3-(fluoro)-5-(chloro)phenyl]-3-fluoropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-37-2P,
(R) -1 - [[(Trifluoromethyl) carbonyl] amino] -1 - [[[1 - [5 - [2 - (carboethoxy) - 3 - [2 - (carboethoxy) - 2 - (carboethoxy) - 3 - [2 - (carboethoxy) - 2 - (carboethoxy) - 3 - [2 - (carboethoxy) - 2 - (carboethoxy) - 2 - (carboethoxy) - 3 - [2 - (carboethoxy) - 2 - (carboethoxy) - (carboethoxy) - (carboethoxy) - (carboethoxy) - (carboethoxy) - (carboethoxy) - (carboetho
 (fluoro)phenyl]-3-fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
669067-38-3P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-
[2-(cyano)-3-(chloro)-5-(chloro)phenyl]-3-fluoropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-39-4P,
 (R) -1 - [[(Trifluoromethyl) carbonyl] amino] -1 - [[[1 - [5 - [2 - (ethoxy) - 3 - (fluoro) - (ethoxy) - 3 - (fluoro) - (ethoxy) - 3 - (ethoxy) - (ethoxy
5-(chloro)phenyl]-3-fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
669067-40-7P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-
 [2-(2-fluoroethoxy)-3-(fluoro)-5-(chloro)phenyl]-3-fluoropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-42-9P,
  (R) -1 - [[(Trifluoromethyl) carbonyl] amino] -1 - [[[1 - [5 - [2 - (ethoxy) - 3 - (fluoro) - (ethoxy) - 3 - (fluoro) - (ethoxy) - 3 - (ethoxy) - (e
5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
669067-46-3P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-1]]669067-46-3P]]
 [2-(2,2,2-trifluoroethoxy)-3-(fluoro)-5-(chloro)phenyl]-3-chloropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-51-0P,
 difluoroethoxycarbonyl)-3-(fluoro)-5-(chloro)phenyl]pyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-53-2P,
 3-(chloro)-5-(fluoro)phenyl]-3-chloropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-54-3P,
  (R) -1 - [[(Trifluoromethyl) carbonyl] amino] -1 - [[[1 - [5 - [2 - (ethoxy) - 3 - (chloro) - (ethoxy) - 3 - (ethoxy) - (e
 5-(fluoro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
669067-58-7P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-
 [2-(ethoxy)-3-(fluoro)-5-(fluoro)phenyl]-3-chloropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-59-8P,
 3-(fluoro)-5-(fluoro)phenyl]-3-chloropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-60-1P,
 trifluoroethoxy)-3-(chloro)-5-(fluoro)phenyl]-3-chloropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-64-5P,
 (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-[2-(ethoxy)-3-(chloro)-1-[[[1-[5-[2-(ethoxy)-3-(chloro)-1-[[1-[5-[2-(ethoxy)-3-(chloro)-1-[1-[1-[5-[2-(ethoxy)-3-(chloro)-1-[1-[1-[5-[2-(ethoxy)-3-(chloro)-1-[1-[1-[5-[2-(ethoxy)-3-(chloro)-1-[1-[1-[5-[2-(ethoxy)-3-(chloro)-1-[1-[1-[5-[2-(ethoxy)-3-(chloro)-1-[1-[1-[5-[2-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(ethoxy)-3-(etho
 5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane
 669067-65-6P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-
 [2-(2,2-difluoroethoxy)-3-(chloro)-5-(chloro)phenyl]-3-chloropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-68-9P,
 (R) -1 - [[(Trifluoromethyl) carbonyl] amino] -1 - [[[1 - [5 - [2 - (2, 2, 2 - (2, 2, 2)]]]]]]
 trifluoroethoxy)-3-(chloro)-5-(chloro)phenyl]-3-chloropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-69-0P
 669067-71-4P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-
 [2-(2,2-difluoroethoxy)-3-(fluoro)-5-(chloro)phenyl]-3-chloropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane 669067-72-5P,
 (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-[[[1-[5-[2-[(cyclopropyl)oxy]-3-[(multiple fill of the fi
 (fluoro)-5-(fluoro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclo
propane 669067-74-7P, (R)-1-[[(Trifluoromethyl)carbonyl]amino]-1-
 [[[1-[5-[2-(cyano)-3-(chloro)-5-(chloro)phenyl]-3-chloropyridin-2-
yl]ethyl]amino]carbonyl]cyclopropane
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
  (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
              (preparation of N-biarylmethylaminocycloalkanecarboxamide as bradykinin B1
              antagonists)
 669066-20-0 HCAPLUS
 Cyclopropanecarboxamide, N-[[3-chloro-5-[3-fluoro-2-(2-methyl-2H-tetrazol-
```

RN

CN

5-yl)phenyl]-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME) .

RN 669066-34-6 HCAPLUS

CN Benzoic acid, 2-fluoro-6-[5-fluoro-6-[[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 669066-47-1 HCAPLUS

CN Benzoic acid, 2-fluoro-6-[5-fluoro-6-[[[[1-[(3,3,3-trifluoro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 669066-48-2 HCAPLUS

CN Benzoic acid, 2-[6-[[[[1-[(dichloroacetyl)amino]cyclopropyl]carbonyl]amino |methyl]-5-fluoro-3-pyridinyl]-6-fluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 669066-49-3 HCAPLUS

CN Benzoic acid, 2-[5-chloro-6-[[[[1-[(trifluoroacetyl)amino]cyclopropyl]carb onyl]amino]methyl]-3-pyridinyl]-6-fluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 669066-50-6 HCAPLUS

CN Benzoic acid, 2-[5-chloro-6-[[[[1-[(2,2-dichloro-1-oxopropyl)amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]-6-fluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 669066-51-7 HCAPLUS

CN Benzoic acid, 2-[6-[[[1-[(chlorodifluoroacetyl)amino]cyclopropyl]carbonyl amino]methyl]-5-fluoro-3-pyridinyl]-6-fluoro-, methyl ester (9CI) (CA

INDEX NAME)

$$\begin{array}{c|c}
 & O \\
 & NH-C-CF_2-C1 \\
 & C=O \\
 & NH-CH_2 \\
 & NH-CH_2
\end{array}$$

$$\begin{array}{c|c}
 & F \\
 & C-OMe \\
 & O
\end{array}$$

RN 669066-52-8 HCAPLUS

CN Benzoic acid, 2-[5-chloro-6-[[[[1-[(chlorodifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]-6-fluoro-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
O \\
NH-C-CF_2-C1 \\
C=O \\
NH-CH_2
\end{array}$$

$$\begin{array}{c|c}
C1 \\
F \\
C-OMe \\
\parallel
O
\end{array}$$

RN 669066-53-9 HCAPLUS

CN Benzoic acid, 2-chloro-6-[5-chloro-6-[[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
C & C1 \\
\hline
C & NH - CH_2 \\
\hline
NH - C - CF_3 \\
\hline
C & C - OMe
\end{array}$$

RN 669066-54-0 HCAPLUS

CN Benzoic acid, 2-chloro-6-[5-chloro-6-[[[[1-[(difluoroacetyl)amino]cyclopro

pyl]carbonyl]amino]methyl]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} O & C1 \\ \hline \\ C-NH-CH_2 & \\ \hline \\ NH-C-CHF_2 & \\ \hline \\ O & C1 \\ \hline \\ C-OMe \\ \hline \\ O & \\ \end{array}$$

RN 669066-55-1 HCAPLUS

CN Benzoic acid, 2-chloro-6-[5-chloro-6-[[[[1-[(chlorodifluoroacetyl)amino]cy clopropyl]carbonyl]amino]methyl]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
 & O \\
 & NH-C-CF_2-C1 \\
 & C=O \\
 & NH-CH_2 \\
 & NH-CH_2
\end{array}$$

$$\begin{array}{c|c}
 & C1 \\
 & C-OMe \\
 & O
\end{array}$$

RN 669066-56-2 HCAPLUS

CN Benzoic acid, 2-chloro-6-[5-fluoro-6-[[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
O & F \\
C-NH-CH_2 & F \\
NH-C-CF_3 & N \\
O & C-OMe \\
O & O
\end{array}$$

RN 669066-57-3 HCAPLUS

CN Benzoic acid, 2-chloro-6-[6-[[[[1-[(dichlorofluoroacety1)amino]cyclopropyl]carbonyl]amino]methyl]-5-fluoro-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 669066-58-4 HCAPLUS

CN Benzoic acid, 2-chloro-6-[6-[[[[1-[(difluoroacetyl)amino]cyclopropyl]carbo nyl]amino]methyl]-5-fluoro-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} O & F \\ \hline \\ C-NH-CH_2 & \hline \\ NH-C-CHF_2 & N \\ \hline \\ O & C-OMe \\ \hline \\ O & O \\ \end{array}$$

RN 669066-59-5 HCAPLUS

CN Benzoic acid, 2-chloro-6-[5-chloro-6-[[[[1-[[[(methoxycarbonyl)amino]carbonyl]amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 669066-60-8 HCAPLUS

CN Benzoic acid, 2-chloro-6-[6-[[[[1-[[[(methoxycarbonyl)amino]carbonyl]amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]-, methyl ester (9CI) (CA

INDEX NAME)

RN 669066-61-9 HCAPLUS

CN Benzoic acid, 4-chloro-2-[5-chloro-6-[[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
C & C1 & C1 \\
C - NH - CH_2 & I \\
NH - C - CF_3 & C - OMe
\end{array}$$

RN 669066-62-0 HCAPLUS

CN Benzoic acid, 2,4-dichloro-6-[5-chloro-6-[[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]-,
methyl ester (9CI). (CA INDEX NAME)

$$\begin{array}{c|c}
C & C1 \\
C - NH - CH_2 & C1 \\
NH - C - CF_3 & N \\
O & MeO - C
\end{array}$$

RN 669066-63-1 HCAPLUS

CN Benzoic acid, 2,4-dichloro-6-[5-fluoro-6-[[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinýl]-,
methyl ester (9CI) (CA INDEX NAME)

RN 669066-64-2 HCAPLUS

CN Benzoic acid, 4-chloro-2-[5-chloro-6-[[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]-6-fluoro-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
C & C1 \\
C & NH - CH_2 \\
NH - C - CF_3 \\
O & MeO - C \\
O & F
\end{array}$$

RN 669066-65-3 HCAPLUS

CN Benzoic acid, 4-chloro-2-fluoro-6-[5-fluoro-6-[[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 669066-67-5 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(chlorodifluoroacetyl)amino]-N-[[3-chloro-5-[3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)

RN 669066-68-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3-fluoro-5-[3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

$$F_{3}C-C-NH$$

$$O$$

$$N=N$$

$$N=N$$

$$F$$

RN 669066-69-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3-chloro-5-[3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-1-[(difluoroacetyl)amino]- (9CI) (CA INDEX NAME)

RN 669066-70-0 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(difluoroacetyl)amino]-N-[[3-fluoro-5-[3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)

RN 669066-71-1 HCAPLUS

CN Cyclopropanecarboxamide, 1-[(chlorodifluoroacetyl)amino]-N-[[3-fluoro-5-[3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)

Me N F F
$$C-NH-CH_2$$
 NH-C-CF2-C1 O

RN 669066-72-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3-chloro-5-[3-chloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
 & C1 \\
 & C-NH-CH_2 \\
 & NH-C-CF_3 \\
 & N \\
 &$$

RN 669066-73-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3-chloro-5-[3-chloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-1-[(difluoroacetyl)amino]- (9CI) (CA INDEX NAME)

RN 669066-74-4 HCAPLUS

CN Cyclopropanecarboxamide, 1-(acetylamino)-N-[[3-chloro-5-[3-chloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)

RN 669066-75-5 HCAPLUS

CN Carbamic acid, [[[1-[[[[3-chloro-5-[3-chloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]amino]carbonyl]cyclopropyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

$$MeO-C-NH-C-NH$$

$$MeO-NH-C-NH$$

$$Me$$

$$N=N$$

RN 669066-76-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3-chloro-5-[5-chloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

$$F_{3}C-C-NH$$

$$O$$

$$Me$$

$$N=N$$

$$C1$$

$$N$$

$$N=N$$

$$C1$$

RN 669066-77-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[[5-[3,5-dichloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
 & C & F & C1 \\
 & C & NH - CH_2 & N & N & C1 \\
 & NH - C - CF_3 & N & N & C1
\end{array}$$

RN 669066-78-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3-chloro-5-[3,5-dichloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
C & C1 \\
C & NH - CH_2 \\
NH - C - CF_3 \\
O & Me \\
N = N
\end{array}$$
C1

RN 669066-79-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3-chloro-5-[5-chloro-3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

$$F_{3}C-C-NH$$

$$O$$

$$N=N$$

$$N=N$$

$$F$$

RN 669066-80-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[[5-[5-chloro-3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

$$F_{3}C-C-NH$$

$$O$$

$$Me$$

$$N$$

$$N$$

$$N$$

$$F$$

$$C1$$

RN 669066-81-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3-chloro-5-[5-chloro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

RN 669066-82-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3-chloro-5-[3,5-dichloro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

RN 669066-83-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[[5-[3,5-dichloro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-3-fluoro-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

RN 669066-85-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[[3-chloro-5-[3,5-dichloro-2-(2,3-difluoropropoxy)phenyl]-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
 & O \\
 & NH-C-CF_3 \\
 & C & O \\
 & NH-CH_2 \\
 & NH-CH_2
\end{array}$$

$$\begin{array}{c|c}
 & C1 \\
 & NH-CH_2 \\
 & NH-CH_2
\end{array}$$

$$\begin{array}{c|c}
 & C1 \\
 & C1
\end{array}$$

$$\begin{array}{c|c}
 & C1 \\
 & C1
\end{array}$$

RN 669066-86-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[[5-[3,5-dichloro-2-(2,3-difluoropropoxy)phenyl]-2-pyridinyl]methyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

RN 669066-87-9 HCAPLUS

CN Carbonic acid, 2-fluoro-6-[5-fluoro-6-[[[[1-[(trifluoroacetyl)amino]cyclop ropyl]carbonyl]amino]methyl]-3-pyridinyl]phenyl methyl ester (9CI) (CA INDEX NAME)

RN 669066-88-0 HCAPLUS

CN Benzoic acid, 2,4-dichloro-6-[5-fluoro-6-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669066-99-3 HCAPLUS.

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]ethyl]-1-[(difluoroacetyl)amino]- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.

Me N N N N C1
$$R$$
 Me R Me

RN 669067-00-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-01-0 HCAPLUS

CN Benzoic acid, 2-chloro-6-[5-chloro-6-[(1R)-1-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-,
methyl ester (9CI) (CA INDEX NAME)

RN 669067-02-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[3-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-03-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[3-fluoro-2-(trifluoromethyl)phenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAMÉ)

$$F_3C$$
 NH
 O
 Me
 CI
 CF_3

RN 669067-04-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[3-fluoro-2-(trifluoromethyl)phenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$
 NH
 O
 Me
 CF_{3}

RN 669067-05-4 HCAPLUS

CN Benzoic acid, 2-chloro-6-[6-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-06-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[5-chloro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

RN 669067-07-6 HCAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-[3-fluoro-5-[3-fluoro-2-(trifluoromethyl)phenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C \xrightarrow{NH} O \xrightarrow{Me} F$$

RN 669067-08-7 HCAPLUS
CN Benzoic acid, 2-chloro-6-[5-fluoro-6-[(1R)-1-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-,
methyl ester (9CI) (CA INDEX NAME)

RN 669067-09-8 HCAPLUS

CN Benzoic acid, 2-chloro-6-[6-[(1R)-1-[[[1-[(difluoroacetyl)amino]cyclopropy l]carbonyl]amino]ethyl]-5-fluoro-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_2CH$$
 O Me F O OMe

RN 669067-10-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[3-chloro-2-(trifluoromethyl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-11-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[2-(difluoromethoxy)-3-fluorophenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

$$F_{3}C \xrightarrow{NH} O \xrightarrow{Me} F$$

RN 669067-12-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[5-chloro-2-(trifluoromethyl)phenyl]- 3-fluoro-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$

$$NH$$

$$O$$

$$Me$$

$$F$$

$$CF_{3}$$

RN 669067-13-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[3,5-dichloro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-1[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

RN 669067-15-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-fluoro-5-[3-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C \xrightarrow{NH} O \xrightarrow{Me} F$$

RN 669067-16-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(2,5-dichlorophenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C \longrightarrow NH \longrightarrow NH \longrightarrow NH \longrightarrow F$$

RN 669067-17-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[2-(2,3-difluoropropoxy)-3-fluorophenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

$$F_3C$$
 NH
 O
 Me
 F
 CH_2F

RN 669067-18-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[2-(2,3-difluoropropoxy)-3-fluorophenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_3C$$
 O
 O
 Me
 O
 CH_2F

RN 669067-19-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[2-(2,2-difluoroethoxy)-3-fluorophenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C \longrightarrow NH \longrightarrow NH \longrightarrow F$$

$$O \longrightarrow CHF_{2}$$

$$O \longrightarrow CHF_{2}$$

RN 669067-20-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[3,5-dichloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-1-

[(trifluoroacetyl)amino] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-21-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[5-chloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-22-5 HCAPLUS

CN Benzoic acid, 2-chloro-6-[5-fluoro-6-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 669067-23-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[5-chloro-3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-1[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-24-7 HCAPLUS

CN Benzoic acid, 4-chloro-2-fluoro-6-[5-fluoro-6-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

RN 669067-25-8 HCAPLUS

CN Benzoic acid, 2-chloro-6-[5-fluoro-6-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-, 2-fluoroethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-26-9 HCAPLUS

CN Benzoic acid, 2,4-dichloro-6-[6-[(1R)-1-[[[1-[(chlorodifluoroacetyl)amino] cyclopropyl]carbonyl]amino]ethyl]-5-fluoro-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-27-0 HCAPLUS

CN Benzoic acid, 2,4-dichloro-6-[6-[(1R)-1-[[[1-[(difluoroacetyl)amino]cyclop ropyl]carbonyl]amino]ethyl]-5-fluoro-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

$$F_{2}CH \longrightarrow NH \longrightarrow Me \longrightarrow F$$

RN 669067-28-1 HCAPLUS

CN Benzoic acid, 4-chloro-2-[5-chloro-6-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-6-fluoro-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-29-2 HCAPLUS

CN Benzoic acid, 2,4-dichloro-6-[5-fluoro-6-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)

$$F_3C$$
 NH
 O
 Me
 F
 O
 OEt

RN 669067-30-5 HCAPLUS

CN Benzoic acid, 4-chloro-2-fluoro-6-[5-fluoro-6-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-, 2-fluoroethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$
 NH
 O
 Me
 F
 O
 O
 $CH_{2}F$

RN 669067-31-6 HCAPLUS

CN Benzoic acid, 4-chloro-2-[5-chloro-6-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-6-fluoro-, methyl ester (9CI) (CA INDEX NAME)

RN 669067-32-7 HCAPLUS

CN Benzoic acid, 4-chloro-2-[5-chloro-6-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-6fluoro-, 2-fluoroethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_3C$$
 NH
 O
 Me
 $C1$
 O
 CH_2F

RN 669067-33-8 HCAPLUS

CN Cyclopropanecarboxamide, 1-(acetylamino)-N-[(1R)-1-[3-chloro-5-[5-chloro-3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-35-0 HCAPLUS
CN Benzoic acid, 4-chloro-2-fluoro-6-[5-fluoro-6-[(1R)-1-[[[1[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-,
ethyl ester (9CI) (CA INDEX NAME)

$$F_{3}C$$
 NH
 O
 Me
 F

RN 669067-37-2 HCAPLUS

CN Benzoic acid, 2-fluoro-6-[5-fluoro-6-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-38-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(3,5-dichloro-2-cyanophenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

RN 669067-39-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(5-chloro-2-ethoxy-3-fluorophenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C \xrightarrow{NH} O \xrightarrow{Me} F$$

RN 669067-40-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[5-chloro-3-fluoro-2-(2-fluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]-1[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-42-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-(5-chloro-2-ethoxy-3-fluorophenyl)-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

RN 669067-46-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[5-chloro-3-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$

$$NH$$

$$O$$

$$Me$$

$$C1$$

$$O$$

$$CF_{3}$$

RN 669067-51-0 HCAPLUS

CN Benzoic acid, 4-chloro-2-fluoro-6-[6-[(1R)-1-[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]ethyl]-3-pyridinyl]-, 2,2-difluoroethyl ester (9CI) (CA INDEX NAME)

RN 669067-53-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[3-chloro-2-(2,2-difluoroethoxy)-5-fluorophenyl]-2-pyridinyl]ethyl]-1[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-54-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-(3-chloro-2-ethoxy-5-fluorophenyl)-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

RN 669067-58-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-(2-ethoxy-3,5-difluorophenyl)-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C \xrightarrow[O]{H} O \xrightarrow[Me]{H} C1$$

RN 669067-59-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[2-(2,2-difluoroethoxy)-3,5-difluorophenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

RN 669067-60-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[3-chloro-5-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_{3}C$$

$$0$$

$$Me$$

$$C1$$

$$CF_{3}$$

RN 669067-64-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-(3,5-dichloro-2-ethoxyphenyl)-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CAINDEX NAME)

RN 669067-65-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-68-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[3,5-dichloro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]-(9CI) (CA INDEX NAME)

RN 669067-69-0 HCAPLUS

CN Benzoic acid, 4-chloro-2-[6-[(1R)-1-[[[1-[(chlorodifluoroacetyl)amino]cycl opropyl]carbonyl]amino]ethyl]-3-pyridinyl]-6-fluoro-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-71-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[5-chloro-2-(2,2-difluoroethoxy)-3-fluorophenyl]-2-pyridinyl]ethyl]-1[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

$$F_{3}C$$

$$O$$

$$NH$$

$$O$$

$$Me$$

$$C1$$

$$C1$$

$$F$$

$$CHF_{2}$$

RN 669067-72-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[2-(cyclopropyloxy)-3,5-difluorophenyl]-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 669067-74-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-(3,5-dichloro-2-cyanophenyl)-2-pyridinyl]ethyl]-1-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

$$F_{3}C$$

$$NH$$

$$O$$

$$Me$$

$$C1$$

$$CN$$

$$CN$$

$$C1$$

$$\begin{array}{c|c} C1 \\ \hline \\ C-NH-CH_2 \\ \hline \\ C-NH-CH_2 \\ \hline \\ N-N \\ \end{array}$$

RN 669066-38-0 HCAPLUS
CN Benzoic acid, 2-[6-[[[1-[[(1,1-dimethylethoxy)carbonyl]amino]cyclopropyl]
carbonyl]amino]methyl]-5-fluoro-3-pyridinyl]-6-fluoro-, methyl ester (9CI)
(CA INDEX NAME)

=> file caold SINCE FILE TOTAL COST IN U.S. DOLLARS SESSION ENTRY 49.89 225.80 FULL ESTIMATED COST DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION -5.46 -5.46CA SUBSCRIBER PRICE

FILE 'CAOLD' ENTERED AT 19:19:31 ON 14 MAR 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.